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ABSTRACT

Binding Interactions of (R)- and (S)-hydroxypropyl-CoM Dehydrogenases
and the Zinc Knuckle Proteins Air1 and Air2

by

Jeremy W. Bakelar, Doctor of Philosophy
Utah State University, 2015

Major Professor: Dr. Sean J. Johnson
Department: Chemistry and Biochemistry

This work is focused on understanding protein function by describing how
paralogous proteins with overlapping and distinct functions interact with their substrates
and with other proteins. Two model systems are the subject of this research: (1) the
stereospecific dehydrogenases R- and S-HPCDH, and (2) the zinc knuckle proteins Air1
and Air2.
R- and S-HPCDH are homologous enzymes that are central to the metabolism of
propylene and epoxide in the soil bacterium Xanthobacter autotrophicus. The bacterium
produces R- and S-HPCDH simultaneously to facilitate transformation of R- and Senantiomers of epoxypropane to a common achiral product 2-ketopropyl-CoM (2-KPC).
Both R- and S-HPCDH are highly stereospecific for their respective substrates as each
enzyme displays less than 0.5% activity with the opposite substrate isomer. Presented
here are substrate-bound x-ray crystal structures of S-HPCDH. Comparisons to the
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previously reported product-bound structure of R-HPCDH reveal structural differences
that provide each enzyme with a distinct substrate binding pocket. These structures
demonstrate how chiral discrimination by R- and S-HPCDH results from alternative
binding of the distal end of substrates within each substrate binding pocket, providing a
structural basis for stereospecificity displayed by R- and S-HPCDH.
Air1 and Air2 are homologous eukaryotic proteins that individually function
within a trimeric protein complex called TRAMP. In the nucleus, TRAMP participates in
RNA surveillance, processing, and turnover by stimulating the 3’-5’ exonucleolytic
degradation of targeted RNAs by the nuclear exosome. Previous studies have indicated
that within TRAMP Air1 and Air2 provide crucial protein-protein interactions that link
the individual subunits of the complex. However, the mechanistic details of these proteinprotein interactions are poorly understood. The work in this dissertation has
characterized a previously unknown binding interface between Air2 and another TRAMP
component, the helicase Mtr4. This interaction may explain how helicase activity is
modulated in TRAMP. In addition to TRAMP protein interactions, preliminary studies
have identified a small region of Air1 that is required for modulating the activity of a
protein that is not found in TRAMP, the methyltransferase Hmt1. Collectively, these
studies provide important characterization of Air1 and Air2 protein-binding interactions,
and establish a foundation for future research efforts aimed at exploring Air protein
function.

(149 pages)
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PUBLIC ABSTRACT

Binding Interactions of (R)- and (S)-hydroxypropyl-CoM Dehydrogenases
and the Zinc Knuckle Proteins Air1 and Air2

by

Jeremy W. Bakelar, Doctor of Philosophy
Utah State University, 2015

Major Professor: Dr. Sean J. Johnson
Department: Chemistry and Biochemistry

A thorough understanding of protein function requires knowledge of how proteins
interact with their substrates and with other proteins. The work entailed in this
dissertation describes the binding interactions of proteins from two different model
systems: (1) the dehydrogenase enzymes R- and S-HPCDH and (2) the zinc knuckle
proteins Air1 and Air2.
R- and S-HPCDH are highly similar enzymes (42% identical) that function in a
unique metabolic pathway found in the soil bacterium Xanthobacter autotrophicus. The
bacterium produces R- and S-HPCDH simultaneously to facilitate the transformation of
two different forms of the organic molecule epoxypropane to a common product that can
be further metabolized and used as a source of energy for the microbe. R- and S-HPCDH
are highly specific for either the right-handed or left-handed form (R- or S- forms) of
their substrate molecules, respectively. Presented here are x-ray crystal structures
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(structural models) of S-HPCDH. Comparisons to the previously reported structure of RHPCDH reveal structural differences that provide each enzyme with a distinct preference
for binding and processing either the R- or S- form of their substrate molecules,
demonstrating a structural basis for substrate preference by R- and S-HPCDH.
Air1 and Air2 are highly similar (45% identical) eukaryotic proteins that
individually function within an essential three-protein complex called TRAMP. In the
nucleus, TRAMP functions in RNA surveillance which is used to monitor different types
of RNA molecules found in the nucleus and stimulate the degradation of any RNAs that
need to be further processed or eliminated. Previous studies have indicated that Air1 and
Air2 are involved in mediating crucial protein-protein interactions that link together the
individual protein subunits of TRAMP. The work in this dissertation characterizes a
previously unknown binding interface between Air2 and another TRAMP proteincomponent, the helicase Mtr4. Importantly, this interaction may explain how the
functional activity of Mtr4 is modulated upon formation of TRAMP, a critical TRAMP
functionality. In addition to protein interactions within TRAMP, this work has also
identified a small region of Air1 that binds and regulates the activity of a protein that is
not part of TRAMP, the methyltransferase Hmt1. Collectively, these studies reveal
important and previously unknown binding interactions of the multifaceted proteins Air1
and Air2, and provide a foundation for future research efforts aimed at understanding
their functions.
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CHAPTER 1
INTRODUCTION I: DEHYDROGENASES OF BACTERIAL EPOXIDE
CARBOXYLATION

During the last century, the increase of human dependence on industrial chemical
processes has resulted in the release of a myriad of potentially detrimental carbon based
compounds into the environment. These environmental contaminants include commonly
recognized greenhouse gases like CO and CO2, and also include many short-chain
unsaturated hydrocarbons such as ethylene, propylene, butylene, and styrene; all of which
are produced on a massive scale worldwide. The epoxides formed from alkenes and their
halogenated counterparts are especially reactive molecules that may have toxic,
mutagenic, and carcinogenic effects on biological organisms [1, 2]. High concentrations
of these hazardous molecules can often be detected in soils and ground water samples in
areas near industrial sites [3], posing a great risk to the local biota and to human health.
Interestingly, several bacterial species have been identified that are capable of
detoxifying and converting short chain (C2-C6) alkenes and epoxides into usable nonreactive central metabolites. One such species is Xanthobacter autotrophicus Py2, which
is capable of growth using propylene or its corresponding epoxide, epoxypropane, as its
sole source of carbon and energy [4]. Bacteria containing such metabolic pathways for
converting alkenes and epoxides into non-harmful molecules are generally believed to
play an essential role in the re-mineralization of this carbon in the global carbon cycle
[3].
It is of considerable interest to understand the biological mechanisms used by
microbes to eliminate various toxic hydrocarbons, as both the whole organisms and the
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enzymes comprising their novel metabolic pathways have potential bioremediation and
biotechnological applications. The focus of research presented in this dissertation is to
gain further insight into the metabolic pathway of epoxide degradation used by the
bacterium X. autotrophicus Py2. Of particular interest are two stereospecific
dehydrogenases which allow the bacterium to metabolize both R- and S- enantiomers of
epoxypropane.

Sources of propylene and epoxypropane
Propylene and its oxidized derivative epoxypropane are generated from both
anthropogenic and biogenic sources. Propylene is a three carbon alkene that is produced
primarily as a byproduct of petroleum refining wherein the process of steam cracking
large hydrocarbon feed-stocks is used to produce other smaller hydrocarbons such as
ethylene. In 2011 it was estimated that the global capacity of industrial propylene
production was nearly 70 million metric tons and expected to increase at a rate of 5%
annually [5]. In the United States, nearly two thirds of the propylene that is produced is
used for the manufacturing of plastics in the form of polypropylene, and 17% is used
directly for the production of epoxypropane (also known as propylene oxide) [6].
Epoxypropane is a highly reactive molecule that is used as a versatile chemical
intermediate for the production of many other compounds. The reactivity of
epoxypropane stems from its strained three-membered ring and propensity to undergo
nucleophilic attack by a number of different compounds including organic and inorganic
acids and bases, alcohols, and amines. The major industrial products derived from
epoxypropane include polyglycol ethers used in polyurethane foams, and propylene
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glycols which are used in a number of applications including polyester resins, chemical
solvents, pharmaceuticals, foods, antifreeze, and many others. By volume propylene and
epoxypropane are amongst the top 50 chemicals produced worldwide [7]. As the
production of these potentially toxic compounds continues to increase, the volume of
propylene and epoxypropane that are emitted into local environments also increases. For
example, since 1983 the annual US emissions of propylene and epoxypropane have been
estimated to have increased from around 440 thousand tons to over 700 thousand tons [8,
9].
In addition to industrial production, propylene and epoxypropane are also
produced, albeit at a much smaller scale, from biological sources. Propylene for example
is one of many small alkenes that are generated and excreted by plant vegetation and
fungi. Propylene is also formed as a product of the combustion of organic materials, i.e.
burning of biomass and fossil fuels [9]. Epoxypropane and other aliphatic epoxides can
be produced biologically in some eukaryotic pathways and by several alkene oxidizing
bacetria. The epoxides generated in vivo are generally short lived intermediate molecules
that are produced by the initial step in biological pathways that are used for alkene
detoxification, or in metabolic pathways that allow some bacteria to utilize alkenes and
epoxides as carbon and energy sources. In each type of pathway, epoxides are produced
by the oxidation of alkenes by alkene monooxygenase enzymes. Alkene monooxygenases
(AMOs) typically exhibit broad substrate specificities and convert various alkenes into
epoxides by incorporating O2 across the olefin bond of the alkene, as illustrated for the
substrate propylene and product epoxypropane in Figure 1-1. Notably, most AMOs are
somewhat stereoselective producing both R- and S- enantiomers of aliphatic epoxides.
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Figure 1-1. Oxidation of propylene catalyzed by alkene monooxygenase.

The monooxygenases used in alkene detoxification pathways include the heme
containing family of cytochrome P450 enzymes found throughout eukaryotes and
prokaryotes [10], and other non-heme containing monooxygenases found exclusively in
prokaryotes [11-13]. AMOs used to generate aliphatic epoxides such as epoxypropane
for carbon and energy sources have been isolated from two bacterial species, X.
autotrophicus Py2 and R. rhodochrous B-276 [14, 15]. In these bacteria, alkene
metabolism is initiated by the epoxidation of alkenes (i.e. propylene to epoxypropane) by
a non-heme di-iron type AMO.

Biological Reactivity of Epoxides
Epoxides are likely to have adverse effects on biological systems. The strong
electrophilic nature of epoxides allows them to readily form covalent adducts with a
number of biological macromolecules, including DNA, RNA, and proteins [2]. In DNA
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and RNA, the reactive nucleophiles are nitrogen atoms of purine and pyrimidine bases. In
proteins, the reactive nucleophiles include nitrogen atoms of the imidazole ring of
histidine, and sulfur atoms found in the side chains of cysteine and methionine residues.
In each case, the biological nucleophile attacks and opens the epoxide oxirane ring,
creating a conjugated product with the nucleophile covalently bound. (Scheme 1-1).

Scheme 1-1.

Such modifications of protein and nucleic acids have profound effects on cellular
functions. Therefore, many aliphatic epoxides, including epoxypropane, are characterized
as having toxic, mutagenic, and carcinogenic effects on living organisms [1, 2]. For
organisms that contain alkene degradation pathways, the initial conversion of an alkene
to epoxide results in a more reactive and potentially harmful compound that must be
quickly transformed into a non-harmful molecule.

Biogenic remediation of epoxides
To circumvent the toxic effects of epoxide reactivity, microbial systems use
nucleophiles other than nucleic acids and protein to react with epoxides and render them
inactive as electrophiles. In these reactions, epoxides are either converted into a less
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detrimental compound which can then be excreted by the microbe (detoxification
pathway), or converted into an organic metabolite that can be used as a source of carbon
and energy via productive metabolism (metabolic pathway). The differences between the
pathways lay in the different nucleophiles that are used to react with the epoxide and the
fate of the product that is formed. In the case of detoxification pathways, many types of
bacteria contain detoxification enzymes such as glutathione S-transferases (GSTs) and
epoxide hydrolayses which use glutathione or water, respectively, as nucleophiles to
attack and open the epoxide ring [16-18] (Figure 1-2A, B). The less reactive product can
then be excreted by the bacterium or used for other biological purposes. In the case of
productive metabolism, several pathways have been characterized in which the first step
involves the nucleophilic addition of a biological molecule such as glutathione or water,
as described above for detoxification pathways. Another strategy for metabolizing
epoxides is found in styrene utilizing bacteria where metabolism of styrene proceeds by
isomerization of styrene oxide to the corresponding aldehyde phenylacetaldehyde [19]
(Figure 1-2C). Another less common strategy is used by several aerobic bacteria that
have been isolated with propylene and epoxypropane as the only source of carbon and
energy. In these pathways a thiol of the atypical cofactor, 2-mercaptoethanesulfonate
(coenzyme M; CoM), is used as the reactive nucleophile which attacks and opens the
epoxide ring, generating a coenzyme M conjugate (Figure 1-2D). The coenzyme M
conjugate is then further metabolized in a series of reactions including a final
carboxylation step producing a molecule of acetoacetate which can then be transformed
into acetyl-CoA for energy production. This unique pathway, which has become known
as the epoxide carboxylation pathway, was initially discovered and characterized within
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Figure 1-2. Biological strategies of epoxide metabolism. (A) Glutathione
transferase, (B) epoxide hydrolase, (C) Styrene oxide isomerase, (D)
epoxyalkane:CoM transferase.

the soil bacterium X. autotrophicus [20, 21] strain Py2, and later extended to R.
rhodochrous strain B276 [22]. Since then, homologues of each of the four enzymes of the
pathway have been found in other alkene metabolizing bacteria including additional
strains of Xanthobacter and R.rhodochrous, Mycobacterium, Pseudomonas, and
Alcaligenes. Overall, the pathway is a very effective way to convert a hazardous 3-carbon
compound into a relatively inert 4-carbon metabolite. Throughout the last decade, there
has been significant interest in understanding the various enzymatic steps of bacterial
epoxide carboxylation, as each of the enzymes in the pathway and the various bacterial
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species that contain them have potential bioremediation and biotechnological
applications.
The epoxide carboxylation pathway of X. autotrophicus Py2
As mentioned previously, the first step in metabolizing short-chain alkenes like
propylene is the oxidative conversion of the alkene into its corresponding epoxide by
AMOs. In X. autotrophicus Py2 the AMO used is a multicomponent NADH-dependent
enzyme that is highly stereoselective, as demonstrated by propylene oxidation in which
the AMO produces a racemic mixture of 95% R-epoxypropane and 5% S-epoxypropane
[15, 21]. In the presence of CO2, both enantiomers of epoxypropane can be effectively
metabolized by the bacterium, as each is transformed into a molecule of acetoacetate
using a three-step four-enzyme pathway called the epoxide carboxylation pathway [21].
The pathway converts R-and S- enantiomers of a variety of short-chain aliphatic epoxides
into a β-keto acid which can then be converted into two molecules of acetyl-CoA (Figure
1-3). Although aliphatic epoxides of varying chain lengths (C2-C6) can be effectively
metabolized via the epoxide carboxylation pathway [3], the most extensively
characterized substrate is epoxypropane [23-25]. Therefore, the following descriptions of
the pathway are in the context of the conversion of epoxypropane to the β-keto acid
acetoacetate. Experimental evidence has indicated that the reactions catalyzed at each of
the three steps are fully reversible. The pathway requires NADPH, NAD+, and fixes a
molecule of CO2.
A multitude of biochemical and structural studies have revealed unique functions
and many mechanistic details of the enzymes at each of the three steps of the epoxide
carboxylation pathway. The first step involves the opening of the epoxide ring and
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Figure 1-3. Three steps of the epoxide carboxylation pathway in X. autotrophicus Py2.
Enzymes catalyzing reactions are written in italics. Green box indicates the second step
which is catalyzed by the two enzymes R-hydroxypropyl-CoM dehydrogenase (RHPCDH) and S-hydroxypropyl-CoM dehydrogenase (S-HPCDH).
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nucleophilic addition of the cofactor CoM. This reaction is catalyzed by the enzyme
epoxyalkane coenzyme M transferase (EaCoMT) [20, 23, 26]. Sequence analysis
indicates that EaCoMT belongs to the Zn-containing alkyl transferase family of enzymes
which catalyze nucleophilic substitution reactions using activated thiols as nucleophiles.
Like other Zn-containing alkyl transferases, EaCoM activates its reactant thiol group
(thiol of CoM) by coordinating it to a Zinc ion. The metal ion coordination lowers the
pKa of the CoM thiol by 1.7 pH units (9.1 to 7.4), facilitating nucleophilic attack by the
now deprotonated thiolate, and subsequent covalent addition of CoM to the aliphatic
epoxide (Figure 1-4) [27, 28]. EaCoMT is unique in the family of Zn-containing alkyl
transferases because it catalyzes a nucleophilic addition reaction rather than a
nucleophilic substitution reaction. The utility of CoM in the pathway is evident in the
remaining two steps, as each of the following three enzymes in the pathway use the
negatively charged sulfonate moiety of CoM as a convenient molecular handle to

Figure 1-4. Covalent addition of CoM to epoxypropane by
epoxyalkane coenzyme M transferase (EaCoMT). A Zinc ion
activates the CoM thiol (colored red) for nucleophilic attack
and subsequent addition of CoM to epoxypropane, producing
R- and S-hydroxypropyl CoM (R- and S- HPC).
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properly orient substrates for catalysis [29-33].
The second step in the pathway, and the focus of Chapter 2 of this dissertation,
involves two dehydrogenase enzymes, (R)-hydroxypropyl-coenzyme M dehydrogenase
(R-HPCDH) and (S)-hydroxypropyl-coenzyme M dehydrogenase (S-HPCDH). These are
homologous enzymes (42% sequence identity) that are highly stereospecific for either the
R- or S-enantiomers of HPC. In this step, both R- and S- HPCDH are used in concert to
convert each enantiomer of HPC into the same achiral product 2-ketopropyl CoM (2KPC). A remarkable feature of R- and S-HPCDH is their ability to discriminate between
R- and S- enantiomers of HPC, as each enzyme exhibits only 0.5%-1% activity when
using the opposite HPC isomer as a substrate [21]. R- and S-HPCDH are members of the
classical short-chain dehydrogenase reductase (SDR) superfamily of enzymes. Enzymes
in this family are NAD(P)(H) dependent enzymes that share a common catalytic tetrad
(Tyr–Lys–Ser–Asn) and catalytic mechanism, as shown for the conversion of R-HPC to
2-KPC in Figure 1-5. In the mechanism shown, the role of the catalytic tetrad residues
and the chemistry around the chiral carbon (C2 in R-HPC) is analogous to the general
mechanism described for other SDR enzymes [34, 35]. Specifically, the tetrad serine
assists in positioning the hydroxyl group of the substrate near the catalytic tyrosine. The
tetrad lysine has a dual role in coordinating NAD+ and in lowering the pKa of the catalytic
tyrosine hydroxyl group through a proton relay that connects the tyrosine, through
hydrogen bonding, to the bulk solvent. The proton relay path is generated through side
chains of three of the catalytic tetrad residues (Tyr-Lys-Asn), hydroxyl group of the
nicotinamide ribose, and water molecules that lead away from the active site to bulk
solvent. In its deprotonated form, the tyrosine acts as a general base abstracting a proton
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from the C2 hydroxyl group of the substrate. A hydride is simultaneously transferred
from the C2 carbon to NAD+, forming NADH and the ketone 2-ketopropyl coenzyme M
(2-KPC) as products.

The final step in the epoxide carboxylation pathway is the CO2 dependent

Figure 1-5. Oxidation of R-HPC by R-hydroxypropyl-coenzyme M
dehydrogenase (R-HPCDH). Binding of the sulfonate moiety of CoM is
indicated by a grey circle. Catalytic tetrad residues (Ser-Tyr-Lys-Asn) are
shown. Tyr155 acts as a general base and a hydride is transferred from R-HPC to
NAD+. A proton relay connects catalytic residues to bulk solvent through water
mediated hydrogen bonding. Image was modified from Sliwa, et al. 2010.

carboxylation of 2-KPC and the regeneration of CoM by the enzyme NADPH:2ketopropyl-CoM carboxylase/oxidoreductase (2-KPCC). Sequence analysis has indicated
that 2-KPCC belongs to the FAD containing NADPH:disulfide oxidoreductase (DSOR)
family of enzymes [36]. All enzymes in this family employ a general mechanistic
strategy in which a reduced form of flavin adenine dinucleotide (FADH) is used to reduce
a conserved cysteine disulfide bond in the active site, which activates the cysteine
residues for catalysis [37]. The cysteine residues proximal and distal, with respect to

13
FAD, are termed the flavin and interchange thiols, respectively. Typical DSOR enzymes
use the activated thiols to catalyze the two electron reduction of a substrate disulfide bond
(Figure 1-6), the interchange thiol attacks one of the sulfur atoms of a substrate disulfide
bond, resulting in disulfide bond cleavage and a mixed disulfide formed between the
interchange thiol and the substrate disulfide. The catalytic cysteine pair is then reoxidized leading to the reduction and subsequent release of the second substrate thiol.

Figure 1-6. Enzymatic steps catalyzed by the DSOR family of enzymes. A substrate with
an oxidized disulfide bond is attacked by the interchange thiol. Oxidation of the catalytic
cysteine pair reduces the covalently bound substrate and the reduced substrate is released.

2-KPCC is unique amongst DSOR enzymes in at least two respects. First, it
catalyzes the reduction of a thioether rather than a disulfide bond. Second, it is the only
known carboxylase within the DSOR family. Mechanistic studies [38] have provided
evidence for a mechanism where the interchange thiol attacks the thioether bond of 2KPC resulting in a mixed disulfide between CoM and the interchange thiol, and the
formation of an enolacetone anion. The enolacetone anion then undergoes carboxylation
producing acetoacetate. Re-oxidation of the catalytic cysteine pair releases CoM, which
can then be reused in the in the first step of the epoxide carboxylation pathway.
The initial mechanistic studies of 2-KPCC left many unanswered questions about
the unique features of its mechanism, including how the substrate is bound, and how the
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highly reactive enolacetone anion is stabilized and carboxylated. A variety of X-ray
crystal structures have provided significant insights to these questions [32, 39, 40]. The
different crystal structures of 2-KPCC include; a substrate-free form (apo-enzyme),
enzyme bound to the substrate 2-KPC, enzyme with a mixed disulfide of CoM, and a
CO2 bound form. The 2-KPC bound structure revealed that the enzyme uses two
positively charged amino acids to bind the sulfonate moiety of CoM. Upon substrate
binding a conformational change occurs that creates a hydrophobic pocket around the
substrate 2-KPC which appears to be accessible only by a small hydrophobic channel,
presumably for CO2. A hydrogen bonding network was also identified in the 2-KPC
bound structure which has been proposed to stabilize the enolacetone anion. The
hydrogen bonding network consists of an ordered water molecule that is hydrogen
bonded to the carbonyl oxygen of 2-KPC and two histidine residues (H84 and H137). It is
presumed that hydrogen bonding by the His-oriented water molecule serves to both
stabilize the enolacetone anion and orient its methylene group for attack on CO2.
The novelty of the epoxide carboxylation pathway is exhibited at each of the three
steps. (1) The usage of CoM, (2) the use of two stereospecific dehydrogenases, and (3)
the fixation of CO2. The discovery of CoM as the 4-carbon carrier in this pathway and the
fixation of CO2 were surprising and unprecedented. Prior to its discovery in this bacterial
pathway, CoM the smallest known biological cofactor, had only been identified to
function in methanogenisis in archaebacterial [41-43]. A Carboxylation step consuming
CO2 had also never been demonstrated in any metabolic pathway used for small
hydrocarbon metabolism. The simultaneous usage of two homologous dehydrogenases in
the same pathway is also a very rare occurrence throughout biology.
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As mentioned above, extensive biochemical and structural studies have revealed
novel functions and mechanisms of the enzymes at each of the pathway steps. However,
the mechanisms that govern stereospecificity of the dehydrogenases R- and S-HPCDH is
a feature that unlike other novel aspects of the pathway, has not been fully characterized.
In addition, because R- and S-HPCDH are homologous enzymes catalyzing the same
reaction but with opposite stereochemistry, they are a great model for studying
mechanisms of stereospecificity in enzyme catalysis, and more specifically, the
mechanisms controlling specificity within the SDR superfamily of enzymes.

SDR superfamily of enzymes
R-and S-HPCDH belong to the classical short-chain dehydrogenase/reductase
(SDR) super family of enzymes. The SDR family represents one of the largest and oldest
enzyme families known with over 60,000 members annotated in sequence databases [44].
The characteristics that define this protein family are chain lengths of approximately 250
amino acids, a large N-terminal domain (Rossman fold) containing a common sequence
motif (TGxxxGxG) for binding NAD(P)(H), a conserved catalytic tetrad (serine, tyrosine,
lysine, asparagine), and a small C-terminal domain that typically functions in substrate
binding . SDR enzymes are arguably the most widely distributed group of enzymes.
Members have been identified throughout the three domains of life and represent multiple
enzyme classes including isomerases, transferases, lyases, and oxidoreductases. Although
these enzymes have conserved residues for binding NAD(P)(H) and catalysis, they have
very broad substrate specificities including substrates such as xenobiotics, steroids,
sugars, and aliphatic alcohols [34, 44, 45].
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Another interesting feature of the SDR superfamily is that despite relatively low
sequence homology (15-30% sequence identity), and diverse substrate preferences, the 3dimensional structures of SDR enzymes (over 400 in the PDB) are clearly homologous
with nearly super-imposable tertiary and quaternary structures. The predominant
structural feature of SDR proteins is a large N-terminal domain composed of a common
α/β-folding pattern characterized by a central β-sheet typical of a Rossmann-fold with
three α-helices on each side (Figure 1-7). It is generally understood that members of the
SDR superfamily utilize this common N-terminal Rossman fold domain as a structural
scaffold in which minor modifications to a smaller C-terminal extension (the C-terminal
domain) confer large differences in substrate preference.
The Rossman fold dinucleotide binding motif is the most common fold found in the
Protein Data Bank (PDB), and the various enzymes of the SDR superfamily highlight the
versatility of this fold in being able to accommodate diverse substrates for various types
of chemical transformations. Because of this versatility, many SDR enzymes have been
targets of enzyme engineering for biocatalysis [46-50]. Of particular interest in multiple
industries is the engineering of stereospecific and stereoselective dehydrogenases that can
be used to produce certain alcohol isomers or clarify racemic mixtures. The potential
commercial value of dehydrogenases within the SDR superfamily for stereospecific and
stereoselective transformations has stimulated significant interest in elucidating the
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Figure 1-7. Ribbon diagram of classical SDR enzyme (3α/20β HSD; PDB: 2HSD)
(A) Tetramer. (B) Monomer; the Rossman fold is depicted with β-strands in red and αhelicies in light blue. The C-terminal domain is colored yellow and NAD+ is shown as
sticks.

catalytic and structural features that govern there mechanisms [49, 51, 52]. Furthermore,
once biochemical and molecular details of a particular enzyme is known, enzymatic
properties such as specificity and selectivity can be modulated through directed evolution
or mutagenesis to fine-tune the enzyme for various functions.
Within the SDR superfamily there are numerous stereospecific enzymes. However,
few stereospecific enzymes have been found to function simultaneously with a
homologous partner-enzyme. Accordingly, R- and S-HPCDH represent a unique and
ideal model system to examine stereospecificity within the SDR superfamily because
they are homologous proteins performing essentially identical chemistry in the same
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pathway, yet both enzymes are highly specific for their respective substrates (R-HPC or
S-HPC).

Mechanistic studies of R-and S-HPCDH
Both R and S-HPCDH have been recombinantly expressed, purified, and
characterized biochemically. Mutagenesis studies have revealed that like the enzyme 2KPCC (the following step in the pathway), Both R- and S-HPCDH possess two
positively charged amino acids that are involved in binding the negatively charged
sulfonate tail (sulfonate moiety of CoM) of the substrate. These residues have been
identified as R152 and R196 in R-HPCDH, and R211 and K214 in S-HPCDH [53, 54].
Site directed mutagenesis of these residues in either enzyme dramatically alters their
ability to oxidize natural substrates, whereas the same mutations do not alter the
oxidation of similar substrates lacking the sulfonate moiety [33, 54]. These studies
suggest that in each enzyme the sulfonate binding amino acids are important contributors
for aligning the natural substrates properly for catalysis. From these studies, it was also
hypothesized that alternative positioning of the substrate binding residues within each
enzyme could be a contributing factor to their opposite stereospecificity.
Inhibition and kinetic analyses have suggested differences in how each enzyme
controls stereospecificity. Inhibition studies showed that the substrate S-HPC is a
competitive inhibitor of R-HPC oxidation in R-HPCDH, with a Kic nearly identical to the
Km of the natural substrate [54]. This observation indicated that R-HPCDH has a similar
preference for binding either substrate (R-HPC or S-HPC). Similar studies performed
with the S-HPCDH enzyme showed that the R-HPC substrate is not a competitive
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inhibitor of S-HPC oxidation [33], indicating that unlike R-HPCDH, the S-enzyme has a
much greater preference for binding its natural substrate S-HPC over R-HPC.
To help clarify differences observed by inhibition studies, a side-by-side kinetic
analysis of R- and S-HPCDH for oxidizing each substrate isomer (R-HPC and S-HPC)
was performed [33]. The catalytic efficiencies (kcat/Km) of each enzyme for its “natural”
substrate isomer are in the range of 1 to 8 x 105. Whereas the catalytic efficiencies of
each enzyme using the opposite substrate isomers are each nearly three-orders of
magnitude lower. Thus, as previously described, both enzymes are highly effective at
discriminating between different HPC stereoisomers. Interestingly, this kinetic study
revealed that stereospecificity in the two enzymes is governed by different kinetic
mechanisms. In the R-enzyme, the difference in catalytic efficiencies between the two
substrates is governed largely by a difference in the values of kcat (turnover rate), which is
402 times lower when using S-HPC as substrate compared to the R-HPC substrate.
Alternatively, in the S-enzyme the difference in catalytic efficiencies between the two
substrates is predominated by a large difference in the value of Km for each substrate (Km
is 209 times higher for R-HPC compared to S-HPC). This increase in Km may be
indicative of an inherent inability of the R-HPC substrate to effectively bind within the
catalytic site of the S-enzyme.
In addition to biochemical characterization, R-HPCDH has been characterized
structurally [30]. A 1.8 Å crystal structure of R-HPCDH bound to NAD+ and the product
2-KPC showed that the enzyme is structurally homologous to other members of the SDR
superfamily. Specifically, like many other SDR enzymes its crystal structure is a tetramer
with each monomer composed of a 2-domain organization (Figure 1-8). The large N-
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Figure 1-8. Ribbon diagram of R-HPCDH (PDB: 2CFC). (A) Tetramer. (B) Monomer;
Rossman fold is depicted with β-strands in red and α-helicies in light blue. The Cterminal domain is colored yellow and NAD+ is shown as lines. The product 2-KPC is
shown with the sulfonate moiety of CoM bound by R196 and R152.
terminal domain is in the form of a Rossman fold composed of seven parallel β-strands
flanked on each side by three α helices. Unambiguous electron density of residues bound
to 2-KPC confirmed that R152 and R196 are used to bind directly to the sulfonate moiety
of CoM. Unfortunately, the positioning of the reactive carbonyl group of 2-KPC at the
catalytic site could not be observed in the crystal structure. Instead, the structure exhibits
the 2-KPC carbonyl group more than seven angstroms from the catalytic tyrosine,
presumably representing a conformation of 2-KPC exiting the active site [30]. In an
attempt to identify structural differences between R- and S-HPCDH, The R-HPCDH
structure was used to construct a homology model of S-HPCDH [33]. As expected, the
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homology model predicted nearly opposite positioning of S-HPCDH sulfonate binding
residues compared to the sulfonate binding residues in R-HPCDH.
Taken together, results from biochemical and structural studies have been used to
formulate a model for stereospecificity in R- and S-HPCDH. According to this “mirror
image” model, opposite stereospecificity of R- and S-HPCDH is obtained via opposite
positioning of sulfonate binding residues in each enzyme, which results in reverse
orientations of the chemical groups attached to the C2 carbon (chiral carbon) of each
substrate relative to a common catalytic site [30, 33, 54]. The different kinetic values
described above for each enzyme can be rationalized by this model in the following way:
In the R-enzyme both substrates can bind at the catalytic site with similar affinity, but a
960-fold increase in catalytic efficiency using R-HPC over S-HPC is achieved because
the R-HPC reactive group is in the proper stereo-orientation for catalysis. When the SHPC substrate binds to the R-enzyme its C2 hydrogen is oriented in the opposite direction
pointing away from NAD+. This opposite orientation inhibits direct hydride transfer from
C2 of the substrate to NAD+, and results in a 402-fold decrease in the value of kcat for
oxidation of S-HPC compared to R-HPC. In the S-enzyme, the R-HPC substrate cannot
effectively bind at the catalytic site because its C2 methyl group is not accommodated
due to steric clashes with amino acid side chains or NAD+, resulting in a 209-fold
increase in the Km value for oxidizing the R-HPC substrate compared to the S-HPC
substrate. Although this model is plausible, it does not describe the actual structural
differences that may account for the observed kinetic differences between the enzymes,
and it cannot be convincingly validated without a comparative structural analysis
between the two enzymes and their substrate binding interactions at the catalytic site.
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Concluding Remarks
The mechanism that governs stereospecificity of R- and S-HPCDH is one of the
last outstanding questions regarding the remarkable pathway of bacterial epoxide
carboxylation. The work described in Chapter 2 of this dissertation provides the first sideby-side structural comparison between R- and S-HPCDH, and the first structural analysis
of how an HPC substrate is aligned within the active site of one of these enzymes (SHPCDH). The results from these studies reveal unique substrate binding pockets
displayed by each enzyme, a structural role of methionine residues within each active
site, and a structural basis for stereospecificity displayed by R- and S-HPCDH.
Furthermore, the structural mechanisms used by this pair of dehydrogenases to
discriminate between two highly similar substrates may provide valuable insight for the
rational design of other enzymes within the SDR superfamily.
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CHAPTER 2
CRYSTAL STRUCTURES OF S-HPCDH REVEAL DETERMINANTS OF
STEREOSPECIFICITY FOR R-AND S-HYDROXYPROPYL-COENZYME M
DEHYDROGENASES1,2

ABSTRACT
(R)- and (S)-hydroxypropyl-coenzyme M dehydrogenases (R- and S-HPCDH) are
stereospecific enzymes that are central to the metabolism of propylene and epoxide in
Xanthobacter autotrophicus. The bacterium produces R- and S-HPCDH simultaneously
to facilitate transformation of R- and S-enantiomers of epoxypropane to a common
achiral product 2-ketopropyl-CoM (2-KPC). Both R- and S-HPCDH are highly specific
for their respective substrates as each enzyme displays less than 0.5% activity with the
opposite substrate isomer. In order to elucidate the structural basis for stereospecificity
displayed by R- and S-HPCDH we have determined substrate bound crystal structures of
S-HPCDH to 1.6 Å resolution. Comparisons to the previously reported product-bound
structure of R-HPCDH reveal that although the placement of catalytic residues within the
active site of each enzyme is nearly identical, structural differences in the surrounding
area provide each enzyme with a distinct substrate binding pocket. These structures
demonstrate how chiral discrimination by R- and S-HPCDH results from alternative
binding of the distal end of substrates within each substrate binding pocket.
1
2
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INTRODUCTION
Propylene metabolism in the soil bacterium Xanthobacter autotrophicus strain
Py2 involves the conversion of chiral epoxides to acetoactetate [1-4]. The initial steps in
the pathway involve the epoxidation of propylene followed by nucleophilic addition of
the small cofactor coenzyme M to the R-and S-enantiomers of epoxypropane, resulting in
a racemic mixture of R- and S-hydroxypropyl CoM (R- and S-HPC, respectively). R- and
S-HPC are then converted into a common achiral product 2-ketopropyl-CoM (2-KPC)
using two highly stereospecific dehydrogenases, (R)-hydroxypropyl-coenzyme M
dehydrogenase (R-HPCDH) and (S)-hydroxypropyl-coenzyme M dehydrogenase (SHPCDH) (Figure 2-1). A remarkable feature of R- and S-HPCDH (40 % sequence
identity) is the extremely high substrate stereospecificity exhibited by these enzymes
(each enzyme displays less than 0.5% activity with the opposite substrate isomer [2]),
although each enzyme catalyzes the same chemical reaction.

Figure 2-1. R-HPCDH and S-HPCDH convert R-and S-hydroxypropyl CoM
(R- and S-HPCDH) to a common product 2-ketopropyl-CoM (2-KPC).
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R- and S-HPCDH have been characterized as members of the “classical” shortchain dehydrogenase/reductase (SDR) superfamily of enzymes. SDR enzymes are found
throughout eukaryotic and prokaryotic species and constitute one of the largest enzyme
families known with over 60,000 members annotated in sequence databases [5]. SDR
enzymes are categorized in several enzyme classes including lyases, isomerases, and
oxidoreductases, and they act on a broad range of substrates including steroids, sugars,
xenobiotics, and aliphatic alcohols [5-7]. Despite the relatively low sequence identity
between SDR enzymes (15-30% sequence identity), structural studies have revealed a
common scaffold that includes N- and C- terminal domains [8]. The N-terminal domain
is a highly conserved Rossman-fold structure that contains a catalytic triad/tetrad (TyrLys-Ser-Asn in the case of R- and S-HPCDH) and a GxxxGxG motif involved in
NAD(P)(H) binding . The C-terminal domain is more variable, both in terms of sequence
and structure, but generally contains a substrate binding loop region that is involved in
substrate binding and specificity [8-11]. Although numerous SDR superfamily enzymes
exhibit stereospecificity, few stereospecific enzymes have been found to function in
concert with a homologous partner-enzyme. R- and S-HPCDH represent an ideal model
system to examine stereospecificity because they perform identical chemistry in the same
pathway, yet both enzymes are highly specific for their respective substrates (R-HPC or
S-HPC).
Several biochemical studies, and a product bound structure of R-HPCDH has led
to a proposed mechanism for R- and S-HPCDH [12-16]. In this mechanism, the role of
the catalytic tetrad residues (Tyr-Lys-Ser-Asn) and the chemistry around the chiral
carbon (C2) is analogous to the general mechanism described for other SDR enzymes [6,
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17]. Specifically, the catalytic tetrad serine assists in positioning the hydroxyl group of
the substrate near the catalytic tyrosine. The tyrosine residue in its deprotonated form acts
as a general base for proton abstraction from the substrate hydroxyl group, and a hydride
is transferred from the C2 carbon of the substrate to NAD+. Lysine has a dual role in
coordinating NAD(H) and in lowering the pKa of the catalytic tyrosine hydroxyl group
through a proton relay involving water molecules and the catalytic tetrad asparagine. The
product bound structure of R-HPCDH reveals a pair of positively charged amino acids
(R152, R196) that coordinate the sulfonate tail of 2-KPC [16]. Kinetic analysis of SHPCDH mutants suggest that positively charged amino acids (R211 and K214) may also
contribute to sulfonate binding in the S-enzyme [15]. It has been proposed that in each
enzyme the sulfonate binding residues are used to properly orient the reactive groups of
the substrate at the catalytic site [13, 15, 16]. Although a crystal structure of R-HPCDH is
available, there are no structures of S-HPCDH. Furthermore, no substrate bound
structures of R- or S-HPCDH are currently available. Here we report high-resolution
binary (NAD+ bound) and ternary (S-HPC/NADH bound) complex crystal structures of SHPCDH. These structures provide insight into the structural architecture of the active site
and substrate binding path of S-HPCDH. In addition, the structures allow for the first
structural comparison between S-HPCDH and R-HPCDH, clarifying structural
mechanisms of stereospecificity employed by these enzymes.
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MATERIALS AND METHODS

Expression, purification, and crystallization
Three sequence variants of S-HPCDH exist on a single megaplasmid in
Xanthobacter autotrophicus strain Py2 [18]. The most well behaved S-HPCDH variant in
vitro (previously designated as S-HPCDH3) was expressed and purified in E. coli as
previously described [15]. Protein was concentrated to 13 mg/ml in the presence of 25 %
glycerol and stored at -80 °C. Protein was thawed on ice and crystallized by sitting drop
vapor diffusion at 4 °C at a 1:1 protein:well drop ratio in a well solution consisting of 0.1
M Bis-Tris, pH 6.5, 0.35M ammonium acetate and 27 % polyethylene glycol 3350.
Crystals of S-HPCDH bound to NAD+ (binary complex) were grown in the presence of
50 µM NAD+ and 50 µM S-HPC. The crystal was transferred directly into a
cryoprotectant composed of the mother liquor, 50 µM S-HPC and 10 % glycerol, and
flash-cooled in liquid nitrogen. S-HPC/NADH bound crystals (ternary complex) were
grown in the presence of 50 µM NADH and 50 µM S-HPC. The crystal was transferred
directly into a cryoprotectant composed of the mother liquor without ammonium acetate,
140 µM S-HPC and 10 % glycerol, and flash-cooled in liquid nitrogen.

Data collection
Diffraction data were generated and collected using a home-source x-ray generator
(Rigaku RU-200 and MicroMax-007HF) and detector (Rigaku R-AXIS IV++). Data were
processed using the HKL2000 program suite [19]. The S-HPCDH crystals belong to space
group P21212 with unit cell dimensions of a= 116 Å, b= 128 Å, and c= 58 Å. Data statistics
are summarized in Table 2-1.
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Structure determination, model building and refinement
The binary complex S-HPCDH structure was solved by molecular replacement
using the R-HPCDH structure ([16], PDB code, 2cfc) as a molecular replacement search
model. The ternary complex structure was solved by molecular replacement using the
refined binary complex as a search model. Molecular replacement was performed using
Phaser [20] from the Phenix program suite [21].
Manual building of the S-HPCDH structures was done using the program COOT
[22]. Electron density maps were high in quality, permitting unambiguous identification
and positioning of the majority of amino acids in each monomer of asymmetric unit.
Discontinuous electron density prohibited modeling of the first two N-terminal amino acids
in each monomer, and a loop region beginning at position 200 and extending to positions
204-207, depending on the monomer. The one exception is one monomer in the ternary
complex structure, in which the entire loop region is observed. Although S-HPC was
included in the crystallization and cryo solutions for the NAD+ bound structure, no electron
density was observed for S-HPC. Instead, an acetate molecule (originating from the
crystallization buffer) was observed at the active site, essentially mimicking the position
of the S-HPC reactive center. Refinement of the S-HPCDH structures were performed
using phenix.refine [23] from the Phenix program suite [21]. Geometry statistics were
calculated using MolProbity [24,25]. The refined coordinates and structure factors were
deposited in the protein data bank under accession ID 4GH5 (binary complex) and 4ITU
(ternary complex). Figures were made using Pymol [26].
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Table 2-1. Data collection and refinement statistics for S-HPCDH structures. Values in
parentheses correspond to those in the outer resolution shell.
S-HPCDH
structure
Data collection
Wavelength (Å)
Resolution range (Å)
Outer shell (Å)
No. of reflections
unique
total
Average redundancy
Mean I/(I)
Completeness (%)
Rsym (%)a
Space group
# of protein molecules/ asym. unit
Unit cell dimensions
a, b, c (Å)
(°)
Refinement
Rwork/Rfree (%)b
Atoms in the structure
protein
waters
ligands
Average B factor (Å2)
protein
water
NAD+/NADH
S-HPC
rmsd bond (Å)/angle (°)
Protein geometry c
Ramachandran outliers (%)
Ramachandran favored (%)
Rotamer outliers (%)
PDB ID
a

Binary
complex

Ternary
complex

1.5418
35.0 - 1.60
1.66 – 1.60

1.5418
35.0 - 1.60
1.66 – 1.60

113,574
708,549
6.2 (2.8)
25.8 (1.9)
98.3 (86.0)
6.3 (38.9)
P21212
4

108,385
1,179,096
10.9 (7.9)
37.0 (3.3)
93.7 (63.9)
5.7 (37.4)
P21212
4

116.1, 127.9, 58.5
90.0, 90.0, 90.0

116.0, 128.4, 58.4
90.0, 90.0, 90.0

17.1/19.9
8,114
6,895
1027
192
13.8
12.5
22.5
11.0
--0.008/1.104

16.4/19.5
8,098
6,977
931
220
14.3
13.2
23.4
11.0
22.4
0.007/1.114

0
98.9
0
4GH5

0
98.1
0.9
4ITU

Rsym= (|(I-<I>)|)/(I), where <I> is the average intensity of multiple measurements.
Rwork = (|Fobs-Fcalc|)/(|Fobs|) and is calculated using all data; Rfree is the R-factor based
on 5% of the data excluded from refinement.
c
Ramachandran statistics were calculated using the MolProbity server [24,25].
b
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RESULTS

Overall structure of S-HPCDH
The binary and ternary crystal structure of S-HPCDH both adopt nearly identical
protein conformations (RMSD = 0.091 Å over 904 residues). The quaternary structure of
S-HPCDH is a homo-tetramer (Figure 2-2), similar to the previously reported structure of
R-HPCDH [16] and other SDR proteins [8]. The tetramer is assembled such that each
subunit interacts with the other three subunits. As shown in Figure 2 (for clarity, subunit
A is described, but analogous interactions are observed for each subunit in the tetramer),
major interactions between subunit A and the other subunits include a four helix bundle
between the long helices D and E of subunits A and C (Figure 2-2, box 1) and several
hydrophobic interactions between the F helices of subunits A and B (Figure 2-2, box 2).
An additional interaction is also observed at the N-termini of each subunit in which
several water molecules are coordinated by R4 and Q237 from each subunit (Figure 2-2,
box 3). A similar N-terminal interaction has not been observed in other SDR family
structures including R-HPCDH, and to our knowledge is a unique feature of S-HPCDH.
The tetramer is further stabilized by a crossover interaction between diagonally spaced
subunits (subunits A and D in Figure 2-2, box 4). This interaction involves adjacent Cterminal carboxylate groups of I258, which coordinate two water molecules. A similar
interaction between C-terminal carboxylate groups was also observed in the R-HPCDH
structure [16].
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Figure 2-2. Tetrameric structure of S-HPCDH. Each subunit of S-HPCDH (labeled a-d)
interacts directly with each of the other three subunits. Direct interactions between
subunit a and the other three subunits are indicated with boxes labeled 1-4.

Each monomer of S-HPCDH has a bipartite domain structure with the active site
located at the bottom of a cleft formed between the N- and C- terminal domains (Figure
2-3). The large N-terminal domain comprises the core of the structure and is in the form
of a NAD(H) binding Rossman-fold motif common to SDR enzymes [8]. The
dinucleotide binding Rossman-fold found in all SDR enzymes is composed of a central
twisted seven-stranded parallel -sheet (A-G) that is flanked on each side by three helices (A-F). In S-HPCDH, D and E are located on the same side of the Rossman
fold and are about twice the length of the other -helices, resulting in an overall Nterminal domain with two -helices that are much longer on one side (Figure 2-3A). Two
loops connect D and E to their respective -strands (D and E to D and E,
respectively), and these long loops constitute one side of the active site cleft.
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Figure 2-3. Monomeric structure of S-HPCDH. (A) Cartoon representation of one of the monomers of S-HPCDH ternary complex.
The N- terminal Rossman fold domain is depicted with β strands colored red, loops colored green, and α-helices colored green. The Cterminal domain is colored yellow. NADH (pink) and S-HPC (gray) molecules are shown as sticks. The region spanning helices FF1
and FF2 is commonly referred to among SDR enzymes as the substrate binding loop. (B) Catalytic site of S-HPCDH ternary
complex. S-HPC is bound with its reactive OH group coordinated between S143 and Y156. The sulfonate tail of S-HPC is
coordinated by T188, R211 and Y215. Water molecules that contribute to a proposed proton relay are shown as red spheres. (C) A
2Fo-Fc omit map surrounding S-HPC and NADH in the ternary structure, contoured at 1 .
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The last several C-terminal residues (following G) and an extensive loop
inserted between F and F fold into a small C-terminal domain. The C-terminal domain
contains two additional -helices (FF1, FF2) that protrude upward forming two sides
of a lobe and the other side of the active site cleft. This lobe is referred to as the substrate
binding loop, following the nomenclature employed for other SDR enzymes [9-11]. In
the SDR superfamily, the substrate binding loop exhibits a high degree of sequence
variation between proteins and often contains residues important for substrate binding
[11]. In the S-HPCDH structure, R211 and K214 (which have been implicated in
substrate binding) are both located on FF2 (Figure 2-3B). The residues connecting
FF1 to FF2 (amino acids 200-204) are observed in one monomer of the ternary
complex, but appear to be somewhat flexible as indicated by high b-factors and
discontinuous electron density for the rest of the monomers in the ternary structure and
all of those in the binary structure.

Active site and substrate binding
The active site of S-HPCDH is located in a cleft between the N- and C-terminal
domains (Figure 2-3). In both the binary and ternary structures, NAD+/NADH bind SHPCDH in an extended conformation along an axis parallel to a plane created by the Ctermini of the central β-sheet. Specific protein interactions are consistent with NAD(H)
binding observed in R-HPCDH and other SDR enzymes [7, 16]. In contrast with the RHPCDH structure, strong electron density is observed for all copies of the entire
NAD+/NADH molecule, including the nicotinamide ring (Figure 2-3C), with average bfactors of 11.0 Å2 for each complex. Since the crystallization experiments for both the
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binary and ternary complexes were performed aerobically, it is possible that NADH was
oxidized to NAD+, which could be difficult to distinguish at 1.6 Å resolution. If NAD+
were present at the active site of the ternary complex (which was co-crystallized with SHPC and NADH), then we would expect a reaction to proceed converting S-HPC to 2KPC. However, S-HPC is clearly observed within the active site of the ternary structure,
suggesting that NADH rather than NAD+ is bound.
In the ternary complex, S-HPC binds in a pocket that extends from above the
nicotinamide ring of NADH toward FF2 of the substrate binding loop (Figure 2-3B).
Each of the four S-HPC molecules is well ordered along its entire length (Figure 2-3C)
with average b-factors of 22.4 Å2. The sulfonate tail of S-HPC is coordinated by T188,
R211 and Y215 (Figure 2-3B). K214 is also located near the sulfonate tail, but electron
density for the terminal side chain atoms is weak and no direct interaction is observed.
One side of the S-HPC binding pocket is entirely composed of residues located on FF1
(M194, G195, L198, and L199), and the other side of the pocket is composed of
hydrophobic residues (V144, A145 and I150) provided by the N-terminal domain. On the
reactive end of the S-HPC molecule, the OH group is coordinated by direct interactions
with the S143 and Y156 side chains. This orientation places the chiral center of S-HPC
directly above the nicotinamide ring of NADH (Figure 2-3B,C).
The observed orientation of S-HPC, NADH and the catalytic tetrad (Y156, K160,
S143, N115) in the ternary complex is consistent with the catalytic mechanism described
for other SDR enzymes [6, 17]. Specifically, the general acid/base Y156 is positioned
between S143 and K160, with its catalytic hydroxyl forming hydrogen bonds with the 2’
hydroxyl of the ribose ring of NADH and the OH group of S-HPC (Figure 2-3B). The 
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amino group of K160 forms a bidentate hydrogen bond with the 2’ and 3’ hydroxyl
groups of the nicotinamide ribose. A water molecule is also observed to be coordinated
between N115 and K160. This water molecule is further coordinated to a string of other
waters, suggesting a proton relay chain connecting the bulk solvent to the active site
tyrosine using N115, K160 and NAD(H) as has been proposed for other SDR family
enzymes [6, 27, 28]. Notably, no conformational differences are observed between binary
and ternary structures for the catalytic tetrad side chains or the residues surrounding the
S-HPC binding site, with the exception of R211.This observation suggests that the
substrate binding pocket is fully configured for S-HPC binding once NAD(H) is bound,
and may be consistent with an ordered binding mechanism for S-HPCDH.

Structural comparison of S-HPCDH and R-HPCDH
The overall structure of S-HPCDH is highly homologous to the R-HPCDH
structure and other SDR family enzymes. The arrangement of the catalytic tetrad is
superimposable between the R- and S- enzymes (RMSD=0.24 Å). However,
superposition of the R-HPCDH and S-HPCDH structures reveals three regions within
each monomer that display different structural conformations: a small shift in the Cterminal end of αB and two larger conformational rearrangements in the substrate binding
region above the active site (Figure 2-4A, B). The shift observed in αB does not appear to
impact the structure of the active site or the substrate binding region, and likely has no
functional consequence. The larger rearrangements directly impact the substrate binding
region and are each centered around a three amino acid insertion/deletion located on a
loop connecting Dand D, and on a loop connecting FF1 and FF2.
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Figure 2-4. Structural differences between R-HPCDH and S-HPCDH. The largest differences center around 3-residue insertions
within each enzyme. Insertions are indicated by ψ in R-HPCDH and by * in S-HPCDH. (A) Superposition of R-HPCDH (gray) and SHPCDH (green). Sites of major structural differences are indicated with boxes. (B) Top view (as compared to view in panel (A)) of
superimposed R- and S-HPCDH structures. Bound molecules (S-HPC in S-HPCDH and 2-KPC in R-HPCDH) are shown as sticks.
Carbon atoms are colored green for S-HPC and gray for 2-KPC (C) View of the 3-residue insertion in R-HPCDH (N93, S94, E95),
and binding of the product 2-KPC at the active site. The backbone carbonyl oxygen atom for N93 is also shown. (D) View of the 3residue insertion in S-HPCDH (S201,D202,T203) and binding of the substrate S-HPC at the active site. The backbone carbonyl
oxygen atoms for L199 and D202 are also shown. (E) Sequence alignment of R- and S-HPCDH. Identical residues are shaded orange;
similar residues are shaded yellow. The positions of the 3-residue insertions are indicated as ψ in R-HPCDH and * in S-HPCDH.
Sulfonate binding residues and catalytic tetrad residues are indicated with diamonds. Residues that contribute to the methionine switch
are shaded blue.
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Repositioning of the loop between D and D results from a loss of three amino acids in
S-HPCDH (Figure 4E). In the R-HPCDH structure, these three residues (N93, S94, and
E95) flank the entrance of the substrate binding pocket, and the main chain carbonyl
oxygen from one of the residues (N93) forms a hydrogen bond to the amide nitrogen of
R152 (Figure 4C). R152 is one of two arginine residues used by the R-enzyme to bind
the sulfonate tail of endogenous substrates and the product 2-KPC [13, 16]. The deletion
of these three residues in S-HPCDH collapses and reconfigures this substrate binding
region such that the binding pocket found in R-HPCDH is lost.
Conversely, three amino acids (residues S201, D202, and T203) are inserted in
the loop between FF1 and FF2 in S-HPCDH (Figure 4D, E). Although the loop
appears to be mobile in the crystal (weak electron density prevented complete modeling
of the loop in 3 of 4 monomers in the ternary structure), the net effect is an opening up of
the space between FF1 and FF2, as compared to R-HPCDH (Figure 4A, B). The
increased separation between FF1 and FF2, combined with amino acid substitutions
in the surrounding region, facilitates formation of a new substrate binding pocket. Main
chain carbonyl oxygen atoms (L199 and D202) from the loop between FF1 and FF2
help orient R211 for S-HPC sulfonate binding through water mediated hydrogen bonds in
a manner analogous to the loop stabilization of R196 observed in the R-HPCDH substrate
binding pocket.
While the three residue insertions/deletions play the most dramatic role in
reconfiguring and repositioning the substrate binding pockets of R- and S-HPCDH, other
sequence differences throughout the region also contribute. Most notably is a
“methionine switch” where M153 in S-HPCDH replaces the sulfonate binding residue
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Figure 2-5. Distinct substrate binding pockets are observed in R-HPCDH- and SHPCDH. (A) Sliced view of S-HPCDH bound to the substrate S-HPC. The shape of the
substrate binding pocket is outlined in green. (B) Sliced view of R-HPCDH bound to the
product 2-KPC. The shape of the substrate binding pocket in R-HPCDH is outlined in
orange. (C) Superimposed outlines of the two substrate binding pockets highlights the
distinct shape and directionality of the distal ends of each substrate binding pocket

R152 of R-HPCDH. Conversely, M187 in R-HPCDH replaces the sulfonate binding
residue T188 of S-HPCDH. In each case, the methionine residue creates a steric block
that closes off the path to the sulfonate binding site observed in the other enzyme (Figure
2-5). The net effect of all these amino acid substitutions and structural rearrangements is
the formation of two distinct substrate binding pockets that are rotated by approximately
60 with respect to each other (Figure 2-5). In each case, the pocket contains residues that
can bind the sulfonate moiety at the distal end of the substrate, which differentially
orients the reactive end of the substrate toward the structurally conserved catalytic site.

DISCUSSION

R-and S-HPCDH represent a rare set of stereospecific enzymes that both function
in a single metabolic pathway to produce the same product from different enantiomeric
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substrates. This provides an ideal system for understanding mechanisms of
stereospecificity. Previous biochemical studies have shown that stereochemical
discrimination is governed by different kinetic parameters in each enzyme [15].
However, a structural understanding of this system has been limited because only the RHPCDH structure was available [15, 16].
In order to more completely understand the structural mechanisms used to achieve
stereospecificity we have now determined the crystal structure of S-HPCDH. It was
previously proposed that specificity of R- and S-HPCDH is controlled in large part by
alternative locations of sulfonate binding residues in each enzyme [13, 15, 16]. In the
current S-HPCDH structure we confirmed that there was alternative placement of
substrate sulfonate binding residues when compared to sulfonate binding residues in the
R-HPCDH structure. Not foreseen, however, was how sequence variations within the
active site cleft of R- and S-HPCDH provide each enzyme with distinct substrate binding
pockets. Significantly, the unique arrangement of these stereospecific pockets doesn’t
appear to arise through a simple inversion of the active site. Rather, each pocket adopts
unique shape and binding characteristics at the site of sulfonate binding (Figure 2-5C).
To visualize how the specific shape and orientation of the substrate binding
pocket in S-HPCDH affects specificity, we modeled R-HPC into the S-HPC binding
pocket of S-HPCDH (Figure 2-6). Effective catalysis for either substrate (S-HPC or RHPC) requires that the C2 (chiral carbon) hydroxyl group is positioned for proton
abstraction between S143 and Y156, and the C2 hydrogen is pointed towards the b-face
of the nicotinamide ring of NAD+ making it available for hydride abstraction [17]. In the
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Figure 2-6. S-HPC and a model of R-HPC within the active site of the S-HPCDH ternary
complex. Both substrates are shown with their C2 hydroxyl group and C2 hydrogen
atoms oriented for effective catalysis. The C2 carbon is indicated with an asterisk (*).
Residues within the active site are displayed with carbon atoms colored green. Carbon
atoms of NADH are colored pink. The surface of the substrate binding pocket is shown as
a gray line. (A) The C2 methyl group of S-HPC is spatially accommodated within the
active site. (B) When R-HPC is properly aligned for catalysis, the C2 methyl group is
directed toward the pocket wall and clashes directly with S143. Insert depicts the
potential clash of the C2 methyl group of R-HPC with S143 of S-HPCDH. The molecular
surface of the methyl group carbon atom (C1) of R-HPC and the side chain oxygen atom
of S143 are shown as dot representation.

ternary complex, the C2 methyl group of S-HPC is positioned within an open region of
the substrate binding pocket where it is free of steric hindrance (Figure 2-6A). In contrast,
when R-HPC is modeled into the catalytic site in the same fashion, the C2 methyl group
of R-HPC is oriented directly toward the wall of the substrate binding pocket, resulting in
significant steric clashes with the side chain of the catalytic serine (S143) (Figure 2-6B).
This observation is consistent with the 290-fold increase in Km observed when R-HPC is
used as a substrate for S-HPCDH [15], and provides a structural basis for
stereospecificity displayed by S-HPCDH.
In summary, several strategies are employed by the R- and S- HPCDH system to
achieve stereospecificity. The enzymes utilize a common catalytic site but reorient the
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substrate binding path as it moves away from the active site. Reorientation of the binding
path is achieved by a three residue insertion/deletion and alternately expands or collapses
the binding pocket and assists in coordinating the distal end of the substrate. Additional
mutations that include a methionine switch further modulate access to and the shape of
the substrate binding path. These strategies may provide a basis for rational design of
stereospecificity in other systems.
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CHAPTER 3
INTRODUCTION II: AIR PROTEINS AND RNA REGULATION

In eukaryotes, RNA levels and RNA quality are tightly regulated
Eukaryotic cells produce a multitude of different types of RNA. In addition to
protein-coding mRNA, the transcriptome is also comprised of many non-coding RNAs
including transfer RNAs (tRNA), ribosomal RNAs (rRNA), small nuclear and nucleolar
RNAs (snRNA and snoRNA), cryptic unstable transcripts (CUT’s), and intergenic
sequences (introns) [1-3]. Most of these non-coding RNAs have direct regulatory roles in
gene expression and translation. After transcription most if not all RNAs are subject to a
variety of maturation events to become fully functional RNAs. These posttranscriptional
modifications often first involve folding of the RNAs into intricate three dimensional
structures, followed by a variety of processing steps such as internal cleavage, end
trimming, and covalent modifications. The cellular levels and quality of RNAs produced
in the cell must be constantly monitored and controlled in order to ensure proper cell
function and survival. In humans, defects in RNA processing and regulation have been
linked to many disease states including neurodegenerative diseases and cancer [4-6],
highlighting the importance of understanding the biological mechanisms controlling
RNA maturation and stability.
In the nucleus of eukaryotic cells RNA biogenesis and stability is regulated by
RNA quality control and surveillance pathways. These pathways are comprised of a
variety of molecular machines including ribonucleases, RNA binding proteins, and many
others, which ensure that only properly processed RNAs are stabilized and all other non-
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functional RNAs – including aberrantly processed RNAs and end-trimmings – are
degraded. In yeast, the nuclear TRAMP complex is required for RNA surveillance and 3’
maturation of many RNAs [7-10]. TRAMP is a three-protein complex composed of an
RNA binding protein (Air1 or Air2), a RNA helicase (Mtr4) and a RNA poly(A)
polymerase (Trf4 or Trf5). Together these proteins identify particular RNAs, and
stimulate their degradation via the 3’-5’ exonuclolytic activities of the RNA exosome, the
primary RNA degrader in the nucleus.
Intricate to TRAMP function are the RNA binding proteins Air1 and Air2
(collectively referred to as Air proteins). The Air proteins are the identifiers of a myriad
of RNA species that are targeted for decay, and they have also been shown mediate
crucial protein-protein interaction within TRAMP [11-13]. In addition to their function
within TRAMP, the Air proteins have also been implicated in regulating the activity of
other proteins that are involved in nuclear mRNA transport [14]. In this role, the Air
proteins may serve a function in RNA quality control by regulating the quality of mRNA
transcripts that are exported to the cytoplasm. Although it is known that the Air proteins
are involved in these various processes, details of how they interact with other proteins
and RNA is lacking. The research presented in the last portion of this dissertation
(Chapters 4-6) aims to further the understanding of Air protein functionality, with
particular focus on the different protein-protein binding interactions that they employ for
various functions.
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The RNA Exosome is required for RNA degradation
In eukaryotes, a multi-protein complex called the RNA exosome serves the
primary role of 3’-5’ RNA degradation in the nucleus and cytoplasm. Essential functions
performed by the exosome include 3’-5’ end-processing of nuclear RNA precursors such
as rRNAs, sn(o)RNAs, and tRNAs, turnover of both non-coding RNA in the nucleus and
protein-coding mRNA in the cytoplasm, and RNA surveillance - where many types of
aberrant non-functional RNAs are identified and degraded [8, 9, 15-21]. Crystal
structures of the exosome from eukaryotes and archaea reveal a conserved structural
architecture throughout species. The exosome is composed of a nine-subunit core (EXO9). Six of these subunits are RNase PH domain containing proteins that form a
hexameric barrel-like structure with a central channel. The other three subunits contain
S1/KH RNA binding domains that assemble into a trimer that caps one side of the barrellike hexamer, forming an entry pore to the central channel [22-24]. This EXO-9 core is
conserved in eukaryotes and archaea. However, in contrast to the archaeal exosome, in
eukaryotes the RNase PH domain proteins that comprise EXO-9 have apparently lost
activity during evolution [23, 24], and nucleolytic activity is instead attained by
association with additional proteins. In S. cerevisieae, the EXO-9 core associates with the
endo- and 3’-5’ exo-ribonuclease Rrp44 (Dis3) to form the catalytically active EXO-10
complex, which functions in both the nucleus and cytoplasm [25]. Structural analyses
have shown that the Rrp44 nuclease associates near the bottom of the exosome core on
the opposite side from the trimeric cap. In this position, unstructured ssRNAs can thread
through the narrow entry pore (10-12 Å across) and into the central channel of the core to
meet the exonucleolytic site of Rrp44 [25, 26]. In the nucleus, EXO-10 also associates

51
with the non-essential 3’-5’exoribonuclease Rrp6 to form the EXO-11 complex [27].
Rrp6 binds to the exosome trimeric cap and is required for particular degradation
functions, such as processing of 5.8S rRNA and distinct processing events of sn(o)RNAs
[28-30].

The RNA exosome requires cofactors
The functional exosome requires additional proteins, collectively called exosome
co-factors, to stimulate its activity and substrate specificity in vivo [31]. The requirement
of protein cofactors is not well understood, but likely involves specific recognition of
RNA substrates and providing an unstructured 3’ end suitable for exonucleolytic
degradation. In S. cerevisiae the major exosome-activating cofactors include two related
DExH-box helicases Mtr4 and Ski2 and their associated proteins. Ski2 is found only in
the cytoplasm where it associates with two putative RNA binding proteins Ski3 and Ski8
to form the physiological multimeric SKI complex [23, 32]. In the cytoplasm the SKI
complex is required for mRNA surveillance and mRNA turnover by EXO-10. The
DExH-box helicase Mtr4 is strictly nuclear, and unlike Ski2, Mtr4 has some independent
functions such as the processing of 5.8S rRNA [27, 33-35]. Mtr4 is also found in a
physiological protein complex called TRAMP, which in addition to Mtr4 contains a RNA
binding protein (Air1 or Air2) and a RNA poly(A) polymerase (Trf4 or Trf5). In budding
yeast, TRAMP is essential and required for nuclear RNA surveillance and processing by
EXO-10 and EXO-11.
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The TRAMP complex is required for nuclear RNA surveillance and processing
The Trf4/5-Air1/2-Mtr4-Polyadenylation complex (TRAMP) of S. cerevisiae was
discovered independently by three different groups in 2005 [9, 31, 36]. These initial
studies indicated that TRAMP is composed of the DExH box RNA helicase Mtr4, a
poly(A) polymerase Trf4, and one of two paralogous zinc knuckle proteins Air1 or Air2
(45% sequence identity). Later studies indicated that another TRAMP complex is formed
by a Trf4 paralog Trf5 (48% sequence identity), which only associates with Air1. Thus,
two types of TRAMP complexes are thought to exist. TRAMP4 contains Mtr4, Trf4, and
either Air1 or Air2, and TRAMP5 contains Mtr4, Trf5, and only Air1. The duplicated Air
and Trf genes likely arose during a whole genome duplication event in S. cerevisiae
about 100 million years ago [37, 38], and therefore other eukaryotes have only one
ortholog of each. In humans, the Air and Trf orthologs are named ZCCHC7 and PAPD5,
respectfully. Furthermore, ZCCHC7 and PAPD5 have been shown to form a trimeric
complex with human Mtr4 (hMtr4) [39], suggesting conservation of the TRAMP
complex between fungi and animals.
TRAMP directly stimulates the nuclear exosome for processing and degradation
of many types of RNA including tRNAs, sn(o)RNAs, rRNAs, pre-mRNAs, CUTs
(cryptic unstable transcripts), and a number of intergenic transcripts [7-10]. In the current
model of TRAMP function (Figure 3-1), Air1/2 identifies particular RNA substrates,
Trf4/5 adds a short (~4-5 nt) poly(A) tail to the 3’ end of the RNA, and Mtr4 unwinds
any RNA secondary structure that may exist [9, 31, 36, 40, 41]. This unwinding and
polyadenylation by TRAMP is presumed to provide an unstructured single stranded 3’
end of the RNA, facilitating its degradation by the exosome [41].
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Figure 3-1. Tramp mediated RNA degradation by TRAMP4 (Trf4, Air2,
and Mtr4). The TRAMP complex identifies RNAs, adds a short 3’ poly(A)
tail (4-5 nt), and stimulates their degradation by the nuclear exosome.

Interestingly, the function of polyadenylation by TRAMP is in contrast to the
traditionally described function of polyadenylation by canonical poly(A) polymerases
(PAPs). In eukaryotes, polyadenylation by PAP stabilizes pre-mRNAs, and requires
recognition of specific sequence elements on the pre-mRNA transcript [42]. On the other
hand, TRAMP polyadenylation stimulates RNA degradation, and TRAMP substrates
have no identifiable similarities in sequence, structure, or function. [40, 41, 43]. After the
initial discovery of TRAMP, a central question was how polyadenylation by PAP
stabilizes RNA, while polyadenylation by TRAMP targets RNA for destruction? Recent
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reports have revealed the likely answer to this question. The key difference governing the
fate of polyadenylated RNA is likely attributed to a marked difference in the length of the
3’ poly(A) tail. The oligo(A) tails appended by PAP are typically several dozen to
hundreds of nucleotides long [44]. Recent data has indicated that the length of oligo(A)
tails appended by TRAMP peaks at 4-5 nucleotides [8]. During pre-mRNA maturation,
addition of at least 12 adenosines are required for binding of the canonical poly(A)
binding protein Pab1, which serves in part to stabilize nuclear mRNA [44]. TRAMP
oligo(A) tails are apparently too short for Pab1 binding, and as a result are left
unprotected and subject to degradation by the exosome [8].

The non-canonical Poly(A) polymerases Trf4 and Trf5
Trf4 was originally identified in a synthetic lethal screen with DNA
topoisomerase I (Top1) mutants, and hence was given the name Topoisomerase I related
function 4 protein. Further genetic studies identified the Trf4 paralog Trf5 (48% sequence
identity) [45]. Neither Trf4 nor Trf5 are individually essential. However, a Trf4Δ Trf5Δ
double mutant is synthetically lethal [45, 46]. Homologues of Trf4 and Trf5 have been
reported throughout eukaryotes including Cid14 in Sz. Pombe, and PAPD5 in humans
[39, 47, 48].
Trf4 and Trf5 are members of the Cid1-family of non-canonical poly(A)
polymerases. Members of the Cid1-family share common features with the canonical
PAP, such as a homologous catalytic domain (NTP transferase domain) and central
domain (PAP-associated domain) [47]. However, unlike the canonical PAP, most Cid1family members lack a recognizable RNA recognition motif (RRM) used to identify and

55
bind RNA substrates. To compensate for lack of an RRM, many Cid1 family members
are presumed to employ additional RNA-binding proteins to target their substrates for
polyadenylation [47], such as Air1 and Air2 homologues in yeast and humans.
Accordingly, the presence of either Air1 or Air2 is required for the polyadenylation
activity of Trf4 in vitro, and Air1Δ Air2Δ cells exhibit loss of polyadenylation of noncoding RNAs in vivo [9, 31, 36].

The zinc knuckle proteins Air1 and Air2
In the TRAMP complex, Air1 and Air2 are involved in protein-protein and
protein-RNA binding interactions. The various binding interactions of Air1 and Air2 and
the implications of their binding interactions are the focus of this dissertation. The Air
proteins were originally identified in a two-hybrid screen as proteins that could interact
with the yeast arginine methyl transferase Hmt1, and were thus given the name Arginine
methyltransferase interacting ring finger proteins [14]. Air1 and Air2 are paralogs that
each contain five adjacent CCHC-type (C-X2-C-X4-H-X4-C) zinc knuckle motifs (also
referred to as ring fingers) located between extended N- and C-terminal sequences
(Figure 3-2). The Air proteins contain 45% sequence identity with the majority of identity
conserved in the region comprising the zinc knuckles (68% sequence identity). Zinc
knuckle motifs (ZnKs) are cysteine rich sequences that structurally fold into reverse turns
to coordinate a zinc metal ion using three cysteine residues and one histidine. ZnKs were
initially characterized in retroviral nucleocapsid proteins where they are used for binding
ssRNA [49]. Many ZnK proteins have also been found throughout eukaryotes from yeast
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to humans, although their functions in eukaryotic systems have not been well
characterized.

Figure 3-2. Air1 and Air2 sequence alignment. Identical sequences are colored orange.
Semi-conserved sequences are colored light yellow. Zinc knuckles (ZnKs) are indicated
by green boxes and ZnK residues are indicated by black triangles
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The Air proteins provide RNA binding in TRAMP
Since the initial discovery of TRAMP, the zinc knuckles of Air1 and Air2 have
been presumed to function as the RNA binding component of the complex. This idea was
first made evident in mutagenesis experiments which showed that polyadenylation of an
aberrant form of a structured RNA (tRNAAla) by a Trf4-Air2 complex was significantly
impaired upon deletion of the three most N-terminal ZnKs of Air2 [12]. This result
correlated with previous experiments (described above) that indicated Air1 and Air2 are
required for Trf4 polyadenylation of RNAs, including polyadenylation of the structured
precursor-RNA hypomodified tRNAiMet [9, 13, 31, 36]. Notably, hypomodified tRNAiMet
is the most well characterized RNA substrate of TRAMP. Recent reports have further
clarified the involvement of Air2 ZnKs in binding aberrant forms of structured RNAs. In
2012, Holub et al. used NMR studies to reveal that binding of hypomodified tRNAiMet by
Air2 involved the second, third, and fourth ZnKs [13]. In that same report, fluorescence
anisotropy experiments showed that an Air2 truncation mutant containing all five ZnKs
could bind directly to an unstructured 12 nucleotide poly(A) oligo with a Kd in the low
micromolar range, suggesting that Air2 ZnKs also bind unstructured RNAs.

Air1 and Air2 provide substrate specificity in TRAMP
In S. cerevisiae, TRAMP4 and TRAMP5 have been shown to have different subnuclear localizations. For example, GFP-fusions of Trf4 and Air2 show that TRAMP4
can be found throughout the nucleus, whereas GFP-fusions of Trf5 and Air1 are primarily
enriched within the nucleolus [11, 50, 51], which is the site of rRNA maturation.
Likewise, Trf5 has been shown to preferentially stimulate degradation of abarrent rRNA
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precursors [52]. This compartmentalization of TRAMP5 could be explained by distinct
substrate specificities between TRAMP complexes provided by either the Trf or Air
components. Because the Air proteins have been shown to be the likely source of
TRAMP RNA binding, they are also the likely source governing TRAMP RNA
specificity [11, 13]. Indeed, a report by Schmidt et al. identified that Air1 and Air2
govern TRAMP substrate specificity for vast number of different RNA types [53]. In that
study a combination of genetic and deep sequencing techniques revealed that both of the
Air proteins have overlapping function in directly stimulating the polyadenylation and
degradation of most types of identified TRAMP substrates, including many rRNAs,
sn(o)RNAs, CUTs, and mRNAs. In addition, the analysis also identified some differences
in specificity between Air1 and Air2. For example, Air2 is independently involved in
stimulating polyadenylation and degradation of several snoRNAs and spliceosomal
RNAs, as well as regulating levels of some mRNA transcripts which code for enzymes
involved in iron and carbon metabolism. Air1 was also shown to be independently
involved in regulating levels of certain mRNAs which code for proteins involved in copy
number control and regulation of the 2µ plasmid found in most yeast strains. Moreover,
the study by Schmidt et al. made clear that the Air proteins are key for providing
substrate specificity in TRAMP and the RNA exosome. However, the question of how
characteristic differences between Air1 and Air2 might control differences in specificity
between different TRAMP complexes is still unknown.
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Air1 and Air2 mediate protein-protein interactions in TRAMP
A central question of TRAMP function has been how the three protein subunits
associate with one another to form a functional complex. Initial studies of TRAMP
indicated that Air2 and Trf4 form a tight complex in vitro. However, identification of the
binding interactions between the two proteins remained elusive until five years later. In
2010, a crystal structure of a minimal Air2-Trf4 heterodimer revealed the binding
interface between Air2 and Trf4 [12]. The crystal structure exhibits only the catalytic and
central domains of Trf4 and the last two zinc knuckles of Air2 (Figure 3-3). In the model,
the last zinc knuckle of Air2 (ZnK5) and sequences within the linker between ZnK4 and
ZnK5 (L4) form direct interactions with the central domain of Trf4. Additional studies
have also shown that recombinant Air2 with mutations in L4 or ZnK5 failed to co-purify
and activate Trf4 [11, 13], indicating that the binding regions observed in the crystal
structure represent the minimal binding interface between Air2 and Trf4. In addition,
ZnK5 is the most conserved zinc knuckle amongst Air2 homologues, and the L4 binding
residues constitute a conserved motif IWRxYxL, found in all Air2 homologues [11, 13].
The Air2 binding surface of Trf4 is also conserved in all Trf4 homologues. These
observations suggest that the Air2-Trf4 binding interface observed in the crystal structure
is phylogenetically conserved across species.
Identifying how Mtr4 associates with the Air2-Trf4 has proven to be more
difficult, and therefore Mtr4 protein-protein interactions within TRAMP remain poorly
characterized. Part of the complexity of identifying protein-binding interactions with
Mtr4 is due to the instability of recombinant Trf and Air proteins that contain extended
sequences beyond those observed in the Air2-Trf4 crystal structure. However, a recent
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Figure 3-3. Crystal structure of a fragment of Air2 with the core domains of Trf4 (PDB
id: 3NYB). (A) Domain organization of Trf4 and Air2. For Trf4 (1-584 aa), the catalytic
domain (161-189, 316-481 aa) is colored grey. The central domain is colored light
yellow. For Air2 (1-301 aa), Zinc knuckles are indicated by green boxes, Trf4 binding
motif IWRxYxL in linker 4 (L4) is indicated by purple lines. Insert box shows sequences
of Air2 ZnK4-ZnK5 with a dashed line indicating residues not observed in the crystal
structure. (B) Cartoon ribbon diagram of the minimum Air2-Trf4 heterodimer. Protein
domains are colored as in panel A. In Air2, zinc ions are shown as orange spheres and
Trf4 binding residues in L4 are colored purple.
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publication indicated that the N-terminus of Air2 is required to co-immunoprecipitate
Mtr4 with an Air2-Trf4 heterodimer, suggesting that Air2 may also facilitate binding to
Mtr4. In Chapter 5 of this dissertation I identify and characterize binding between a small
peptide fragment of Air2 and Mtr4, revealing a binding interaction used by Air2 to bridge
the three protein subunits of TRAMP.

Air proteins are regulators of the methyltransfease Hmt1 and mRNA export.
As mentioned previously, the Air proteins were initially identified as proteins that
interact with the yeast arginine methyltarnsferase Hmt1 [14]. In that study, Air1 and Air2
were shown to directly bind Hmt1 in yeast two- hybrid assays in which the RGG-box
domain of the mRNA transport protein Npl3 was used as bait. The RGG-box domain of
Npl3 is both a site used for binding mRNAs that are shuttled to the cytoplasm, and a site
of methylation by Hmt1. In budding yeast, nuclear export of Npl3, and thus export of its
mRNA cargo, requires methylation by Hmt1. Furthermore, Air1 was shown to inhibit
Hmt1 methylation of Npl3 in vitro and in vivo, suggesting that binding of Air1 to Hmt1
inhibits methylation, and thus inhibits mRNA export. To verify this model in vivo, Npl3
and mRNA localization was analyzed in S. cerevisiae strains containing single gene
deletions of Air1 and Air2, and Air1Δ Air2Δ double mutant strains. The single gene
deletions had no observable effect on cell viability or Npl3/RNA transport. However,
double mutant strains had a severe growth defect, suggesting some functional overlap of
Air1 and Air2. The double mutant strain also exhibited nuclear retention of Npl3 and
accumulation of Poly(A) mRNAs in the nucleus. Collectively these experiments
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indicated that indeed the Air proteins can regulate methylation activity of Hmt1 and
influence nuclear mRNA transport.
Modification of proteins by arginine methylation serves many critical functions.
For example, in eukaryotes arginine methylation is involved in RNA processing,
transcriptional regulation, signal transduction, and DNA repair [54]. Currently, Air1 is
the only known protein that has been demonstrated to regulate the activity of arginine
methylation in S. cerevisiae. Understanding the mechanistic details of Hmt1 regulation
would provide valuable insight to how arginine methylation is regulated endogenously. In
Chapter 6 of this dissertation I describe my own research efforts aimed at understanding
the interaction between the Air proteins and Hmt1, and also outline future directions for
that research.

The DExH-box helicase Mtr4
The RNA helicase Mtr4 was first identified in a yeast genetic screen for
identifying mutants that accumulate Poly(A) RNA in the nucleus. At that time, it was
presumed that the accumulated poly(A) RNAs were mRNAs, and therefore the name
mRNA transport 4 was given [55]. Mtr4 was the first characterized exosome co-factor,
and current knowledge indicates that Mtr4 and its homologues (including other Ski2-like
helicases) are required for all known exosome functions in vivo. Mtr4 homologues and
associated protein complexes have been identified across species from fungi to humans.
In S. cerevisiae Mtr4 can function independent of other proteins to stimulate the
exosome, such as 5.8s rRNA processing [27, 33-35]. However, the majority of
characterized functions of Mtr4 are in the context of the TRAMP complex. Like other
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Ski2-like helicases, Mtr4 has 3’-5’ unwinding activity and RNA dependent ATPase
activity. It is generally presumed that the helicase function of Mtr4 is used to prepare
RNA substrates for exosome degradation by unwinding RNA secondary structure and
displacing bound proteins from ribonucleoprotein complexes.
Crystal structures of Mtr4, including apo and RNA-bound forms have provided
insight into Mtr4s domain architecture and RNA binding path (Figure 3-4) [34, 56].
Similar to other Ski2-like helicases, Mtr4 has a four-domain helicase core that is
composed of two canonical RecA-like folds (domains 1 and 2), a winged helix domain
(domain 3), and a helical bundle domain, also referred to as the ratchet helix domain
(domain 4). A large 256 amino acid insertion (arch domain) is also observed to be
inserted into the winged helix domain. The arch domain is a prominent feature that rises
above the helicase core and terminates in a globular structure called the fist (also called
the KOW domain) [34, 56]. The arch domain is unique to Mtr4 and other Ski2-like RNA
helicases. Notably, in Mtr4 the arch domain is not required for helicase activity or
binding to Air2-Trf4, but is required for 5.8S rRNA processing in vivo and binding
tRNAiMet in vitro [34, 56]. In all DExH-box helicases, the RecA1 and RecA2 domains
contain conserved sequence motifs for binding and hydrolysis of ATP, a requirement for
helicase function [57]. In the structures of Mtr4, the RecA domains pack against the
winged helix and ratchet helix domains, forming a central channel for ssRNA. [34, 56].
To visualize RNA duplex unwinding in Mtr4, the apo-Mtr4 model was used to
construct a model of nucleic acid duplex unwinding according to the DNA bound
structure of the Ski2-like DNA helicase Hel308 (Figure 3-4-B) [34]. The duplex
unwinding model shows that a conserved β-hairpin loop in the second RecA domain
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Figure 3-4. Crystal structure of Mtr4 (PDB id: 3L9O) (A) Domain organization of
Mtr4. Domain names are shown. The winged helix domain is abbreviated as W. (B)
Cartoon ribbon diagram of Mtr4 (residues 74-1073) from S. cerevisiae. Domains are
colored as in panel A. To visualize binding of double-stranded nucleic acid, the apoform structure was modeled with partially unwound nucleic acid from the Hel308
structure (Jackson et al., 2010). The -hairpin loop (colored green) extends from
RecA2 and facilitates strand separation.
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facilitates strand separation as the RNA enters into the central channel. As the nucleic
acid passes through the channel it contacts each of the RecA domains and the ratchet
helix domains before it exits the helicase at the base. Furthermore, the surface of the
RNA exit site appears to be structured to accommodate the dimensions of the EXO9 core,
and thus it has been proposed that Mtr4 feeds RNA directly into the exosome [34].

In TRAMP, Mtr4 modulates Poly(A) tail length
As previously mentioned, TRAMP primarily adds only five adenosines to the
3’end of its RNA targets in vivo [8]. Several studies have identified that this poly(A) tail
length restriction is due to a secondary functional activity of Mtr4. Mtr4 was first
implicated in regulating Poly(A) tail length in studies by the Tollervey lab, which showed
Mtr4 depletion in vivo results in hyperadenylation of TRAMP substrates [52]. More
recently, in vitro studies by the Jankowsky lab revealed that in the context of TRAMP,
Mtr4 stimulates polyadenylation by Trf4 until approximately four adenosines are added
to the RNA [58]. After the critical number of four adenosines is added, polyadenylation is
markedly suppressed, and when Mtr4 is removed, poly(A) restriction is abolished,
suggesting that Mtr4 modulates poly(A) tail length. Mutations that prevent helicase
unwinding activity further indicated that modulation of polymerase activity was not due
to the unwinding activity of Mtr4. Other studies by the Jankowsky lab have showed that
isolated Mtr4 and TRAMP both have a distinct preference for unwinding RNA substrates
with a 4-6 nt poly(A) tail [59]. Together, these results indicate that Mtr4 possesses an
inherent poly(A) sensing mechanism independent of helicase function, which allows the
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helicase to identify the number of 3’adenosines and stimulate Poly(A) addition until the
preferred number of terminal adenosines is acquired.
Modulating the activity of another protein by identifying particular nucleic acid
features is unprecedented amongst RNA helicases. Central to this unique function is
Mtr4s ability to identify and discriminate between substrates that have a poly(A) tail and
those that do not. A recent publication by our group [60] revealed that Mtr4 uses specific
sequences located on the ratchet helix of domain 4 to identify RNA poly(A) tails.
Specifically, R1030 (conserved in Mtr4 homologues) is used to detect 3’ poly(A)
sequences and promote unwinding of polyadenylated RNA substrates in vitro. Mutation
of R1030 resulted in decreased unwinding rates of polyadenylated RNA to levels
comparable to substrates without a poly(A) tail. These findings correlate with the RNAbound crystal structure which showed direct interactions between R1030 and a RNA
adenine base.

Mtr4 helicase activity is stimulated by TRAMP
Another interesting feature of Mtr4 function is that its RNA unwinding rate is
enhanced by nine-fold in the context of TRAMP [59]. Because Mtr4 has some functions
independent of TRAMP, this regulation of Mtr4 activity could be used to help avoid the
energy cost of unwinding substrates that have not first been identified by TRAMP.
Intriguingly, the increase in unwinding activity upon TRAMP formation is observed
regardless of poly(A) tail length, suggesting that formation of TRAMP independently
facilities modulation of both Trf4 polyadenylation and Mtr4 helicase activity. However,
it is not clear how Mtr4s interaction with Air2-Trf4 stimulates helicase unwinding rates.
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One possibility is that binding of Air2-Trf4 causes a structural rearrangement of Mtr4
that improves RNA substrate binding, ATP binding, or ATPase activity. Such proteininduced conformational changes have been demonstrated to enhance helicase activity for
a variety of DExH-box helicases [61-64]. Comparatively, in vitro studies show that
TRAMP has an elevated ATP binding affinity compared to Mtr4 alone, and importantly,
this increased affinity for ATP is not due to the adenylation activity of Trf4 (which also
requires ATP). This observation raises the possibility that binding of Mtr4 to Air2-Trf4
increases Mtr4s ATP binding affinity, which could facilitate the enhanced helicase
activity observed in TRAMP. A better understanding of helicase activity modulation in
TRAMP requires additional knowledge of how the Air2-Trf4 heterodimer interacts with
Mtr4. Accordingly, in Chapter 5 of this dissertation, I a direct binding interaction is
identified between Air2 and the ATP binding domains of Mtr4 (RecA domains).

Concluding remarks
The central goal of research presented in the following chapters of this
dissertation is to extend the functional and mechanistic characterization of Air1 and Air2
in the context of their various binding interactions and physiological implications therein.
Air1 and Air2 are functionally multi-faceted proteins capable of associating with various
protein-partners and RNA species to regulate the cellular levels many RNA types. In
Chapter 5, a previously unknown binding interface is identified between Air2 and the
TRAMP complex component Mtr4. That work successfully narrows down an Air2-Mtr4
binding interface that includes the first 29 amino acids of Air2 and the RecA domains of
Mtr4. This interaction likely explains a key functionality of helicase regulation in
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TRAMP. Chapter 6 describes preliminary studies and directions for future efforts aimed
at characterizing the binding interactions of Air proteins to Mtr4, and the
methyltransferase protein Hmt1. Collectively, these efforts provide important
characterization of Air1 and Air2 protein binding interactions with different protein
binding-partners, and provide a foundation for future research aimed at understanding Air
protein function.

REFERENCES
[1]

P.P. Amaral, M.E. Dinger, T.R. Mercer, J.S. Mattick, Science 319 (2008) 17871789.

[2]

C.A. Brosnan, O. Voinnet, Current Opinion in Cell Biology 21 (2009) 416-425.

[3]

J.E. Wilusz, H. Sunwoo, D.L. Spector, Genes & Development 23 (2009) 14941504.

[4]

D. Astuti, M.R. Morris, W.N. Cooper, R.H. Staals, N.C. Wake, G.A. Fews, H.
Gill, D. Gentle, S. Shuib, C.J. Ricketts, T. Cole, A.J. van Essen, R.A. van Lingen,
G. Neri, J.M. Opitz, P. Rump, I. Stolte-Dijkstra, F. Muller, G.J. Pruijn, F. Latif,
E.R. Maher, Nature Genetics 44 (2012) 277-284.

[5]

A.G. Bassuk, Y.Z. Chen, S.D. Batish, N. Nagan, P. Opal, P.F. Chance, C.L.
Bennett, Neurogenetics 8 (2007) 45-49.

[6]

A.V. Philips, T.A. Cooper, Cellular and Molecular Life Sciences 57 (2000) 235249.

[7]

S. San Paolo, S. Vanacova, L. Schenk, T. Scherrer, D. Blank, W. Keller, A.P.
Gerber, PLoS Genetics 5 (2009) e1000555.

69
[8]

W. Wlotzka, G. Kudla, S. Granneman, D. Tollervey, EMBO J. 30 (2011) 17901803.

[9]

F. Wyers, M. Rougemaille, G. Badis, J.C. Rousselle, M.E. Dufour, J. Boulay, B.
Regnault, F. Devaux, A. Namane, B. Seraphin, D. Libri, A. Jacquier, Cell 121
(2005) 725-737.

[10]

K.Y. Kong, H.M. Tang, K. Pan, Z. Huang, T.H. Lee, A.G. Hinnebusch, D.Y. Jin,
C.M. Wong, Nucl. Acids Res. 42 (2014) 643-660.

[11]

M.B. Fasken, S.W. Leung, A. Banerjee, M.O. Kodani, R. Chavez, E.A. Bowman,
M.K. Purohit, M.E. Rubinson, E.H. Rubinson, A.H. Corbett, J. Biol. Chem. 286
(2011) 37429-37445.

[12]

S. Hamill, S.L. Wolin, K.M. Reinisch, J. Biol. Chem. 107 (2010) 15045-15050.

[13]

P. Holub, J. Lalakova, H. Cerna, J. Pasulka, M. Sarazova, K. Hrazdilova, M.S.
Arce, F. Hobor, R. Stefl, S. Vanacova, Nucl. Acids Res 40 (2012) 5679-5693.

[14]

K. Inoue, T. Mizuno, K. Wada, M. Hagiwara, J. Biol. Chem. 275 (2000) 3279332799.

[15]

T. Carneiro, C. Carvalho, J. Braga, J. Rino, L. Milligan, D. Tollervey, M. CarmoFonseca, Molecular and Cellular Biology 27 (2007) 4157-4165.

[16]

B. Das, S. Das, F. Sherman, Proc. Natl Acad Sci USA 103 (2006) 10871-10876.

[17]

C.A. Davis, M. Ares, Jr., Proc. Natl Acad Sci USA 103 (2006) 3262-3267.

[18]

C. Dez, J. Houseley, D. Tollervey, EMBO J. 25 (2006) 1534-1546.

[19]

P. Grzechnik, J. Kufel, Molecular Cell 32 (2008) 247-258.

[20]

P. Hilleren, T. McCarthy, M. Rosbash, R. Parker, T.H. Jensen, Nature 413 (2001)
538-542.

70
[21]

S. Kadaba, A. Krueger, T. Trice, A.M. Krecic, A.G. Hinnebusch, J. Anderson,
Genes & Development 18 (2004) 1227-1240.

[22]

K. Buttner, K. Wenig, K.P. Hopfner, Molecular Cell 20 (2005) 461-471.

[23]

J. Houseley, J. LaCava, D. Tollervey, Nature Reviews 7 (2006) 529-539.

[24]

Q. Liu, J.C. Greimann, C.D. Lima, Cell 127 (2006) 1223-1237.

[25]

F. Bonneau, J. Basquin, J. Ebert, E. Lorentzen, E. Conti, Cell 139 (2009) 547-559.

[26]

D.L. Makino, M. Baumgartner, E. Conti, Nature 495 70-75.

[27]

C. Allmang, E. Petfalski, A. Podtelejnikov, M. Mann, D. Tollervey, P. Mitchell,
Genes & Development 13 (1999) 2148-2158.

[28]

R.K. Gudipati, Z. Xu, A. Lebreton, B. Seraphin, L.M. Steinmetz, A. Jacquier, D.
Libri, Molecular Cell 48 (2012) 409-421.

[29]

A. Lardenois, Y. Liu, T. Walther, F. Chalmel, B. Evrard, M. Granovskaia, A.
Chu, R.W. Davis, L.M. Steinmetz, M. Primig, Proc. Natl Acad Sci USA 108
1058-1063.

[30]

E. Thomson, D. Tollervey, Molecular and Cellular Biology 30 976-984.

[31]

J. LaCava, J. Houseley, C. Saveanu, E. Petfalski, E. Thompson, A. Jacquier, D.
Tollervey, Cell 121 (2005) 713-724.

[32]

J.T. Brown, X. Bai, A.W. Johnson, RNA 6 (2000) 449-457.

[33]

J. de la Cruz, D. Kressler, D. Tollervey, P. Linder, EMBO J. 17 (1998) 11281140.

[34]

R.N. Jackson, A.A. Klauer, B.J. Hintze, H. Robinson, A. van Hoof, S.J. Johnson,
EMBO J. 29 (2010) 2205-2216.

[35]

S. Kadaba, X. Wang, J.T. Anderson, RNA 12 (2006) 508-521.

[36]

71
S. Vanacova, J. Wolf, G. Martin, D. Blank, S. Dettwiler, A. Friedlein, H. Langen,
G. Keith, W. Keller, PLoS Biology 3 (2005) e189.

[37]

M. Kellis, B.W. Birren, E.S. Lander, Nature 428 (2004) 617-624.

[38]

C. Seoighe, K.H. Wolfe, Proc. Natl Acad Sci USA 95 (1998) 4447-4452.

[39]

M. Lubas, M.S. Christensen, M.S. Kristiansen, M. Domanski, L.G. Falkenby, S.
Lykke-Andersen, J.S. Andersen, A. Dziembowski, T.H. Jensen, Molecular Cell
43 624-637.

[40]

J.T. Anderson, X. Wang, Critical Reviews in Biochemistry and Molecular
Biology 44 (2009) 16-24.

[41]

J. Houseley, D. Tollervey, Biochimica et Biophysica Acta 1779 (2008) 239-246.

[42]

W. Keller, Cell 81 (1995) 829-832.

[43]

X. Wang, H. Jia, E. Jankowsky, J.T. Anderson, RNA 14 (2008) 107-116.

[44]

A.B. Sachs, R.W. Davis, R.D. Kornberg, Molecular and Cellular Biology 7
(1987) 3268-3276.

[45]

B.U. Sadoff, S. Heath-Pagliuso, I.B. Castano, Y. Zhu, F.S. Kieff, M.F. Christman,
Genetics 141 (1995) 465-479.

[46]

Z. Wang, I.B. Castano, A. De Las Penas, C. Adams, M.F. Christman, Science 289
(2000) 774-779.

[47]

A.L. Stevenson, C.J. Norbury, Yeast 23 (2006) 991-1000.

[48]

T.Z. Win, S. Draper, R.L. Read, J. Pearce, C.J. Norbury, S.W. Wang, Molecular
and Cellular Biology 26 (2006) 1710-1721.

[49]

V. D'Souza, M.F. Summers, Nature Reviews Microbiology 3 (2005) 643-655.

72
[50]

W.K. Huh, J.V. Falvo, L.C. Gerke, A.S. Carroll, R.W. Howson, J.S. Weissman,
E.K. O'Shea, Nature 425 (2003) 686-691.

[51]

C. Walowsky, D.J. Fitzhugh, I.B. Castano, J.Y. Ju, N.A. Levin, M.F. Christman,
J. Biol. Chem. 274 (1999) 7302-7308.

[52]

J. Houseley, D. Tollervey, EMBO Reports 7 (2006) 205-211.

[53]

K. Schmidt, Z. Xu, D.H. Mathews, J.S. Butler, RNA 18 1934-1945.

[54]

M.T. Bedford, S. Richard, Molecular Cell 18 (2005) 263-272.

[55]

T. Kadowaki, S. Chen, M. Hitomi, E. Jacobs, C. Kumagai, S. Liang, R. Schneiter,
D. Singleton, J. Wisniewska, A.M. Tartakoff, J. of Cell Biology 126 (1994) 649659.

[56]

J.R. Weir, F. Bonneau, J. Hentschel, E. Conti, Proc. Natl Acad Sci USA 107
(2010) 12139-12144.

[57]

M.R. Singleton, M.S. Dillingham, D.B. Wigley, Annual Review of Biochemistry
76 (2007) 23-50.

[58]

H. Jia, X. Wang, F. Liu, U.P. Guenther, S. Srinivasan, J.T. Anderson, E.
Jankowsky, Cell 145 (2012) 890-901.

[59]

H. Jia, X. Wang, J.T. Anderson, E. Jankowsky, Proc. Natl Acad Sci USA 109
(2012) 7292-7297.

[60]

L.L. Taylor, R.N. Jackson, M. Rexhepaj, A.K. King, L.K. Lott, A. van Hoof, S.J.
Johnson, Nucl. Acids Res 42 (2014) 13861-13872.

[61]

N.L. Korneeva, E.A. First, C.A. Benoit, R.E. Rhoads, J. Biol. Chem. 280 (2005)
1872-1881.

73
[62]

J.P. Staley, J.L. Woolford, Jr., Current Opinion in Cell Biology 21 (2009) 109118.

[63]

N. Tanaka, A. Aronova, B. Schwer, Genes & Dev. 21 (2007) 2312-2325.

[64]

T. Tanaka, T. Mizukoshi, K. Sasaki, D. Kohda, H. Masai, J. of Biolog. Chem. 282
(2007) 19917-19927.

74
CHAPTER 4
A COMPREHENSIVE DESCRIPTION OF METHODS USED TO CHARACTERIZE
AIR PROTEINS

ABSTRACT
Many methodologies have been developed in order to conduct structural and
biochemical studies of Air-proteins and other TRAMP components. These methods
include construction of expression constructs, purification strategies, protein binding
studies, and crystallization. Methods were also developed for conducting binding studies
and initiating crystallization trials. This chapter describes detailed methods used to
characterize TRAMP proteins, with a particular emphasis on Air1 and Air2. The
expression constructs and purification strategies mentioned are those that have produced
the greatest amount of protein expression and purification yields.

INTRODUCTION
All three protein subunits of TRAMP including both of the Air proteins (Air1 and
Air2), Trf4, and Mtr4 has been studied as part of this dissertation work. Many obstacles
were overcome to develop methods for protein expression and purification of isolated
proteins and protein co-complexes. Assays for characterizing protein binding interactions
were also developed, and several crystallization studies for TRAMP proteins have been
initiated.
One of the major obstacles encountered during this research was the difficulty of
expression and purification of recombinant TRAMP proteins. At the beginning of this
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dissertation work the only protein subunit of TRAMP that had been successfully
expressed in E.coli was Mtr4. My efforts started with developing a protocol to express
and purify isolated Trf4. Initial protein expression trials were conducted using various
expression and growth parameters in both E.coli and yeast. To overcome difficulties in
expression and solubility, a protein refolding protocol was developed that could
successfully isolate a soluble form of truncated Trf4.
A soluble full-length form of Trf4 was later obtained by co-expressing Trf4 with
another TRAMP component, the zinc knuckle protein Air2. Both proteins were coexpressed on a single plasmid (pET-Duet1) which resulted in soluble Trf4-Air2
complexes that could be purified. In addition to full length proteins, different truncation
mutants of Trf4 and Air2 were also cloned into the same co-expression plasmid. These
constructs also produced soluble Trf4-Air2 complexes that were purified and used for
many crystallization screening trials. Unfortunately, none of those trials have produced
protein crystals. However, those expression constructs and purifications methods will
likely be of value for future functional and structural studies.
The greatest amount of success in expression and purification of TRAMP
complex proteins has been with the zinc knuckle proteins Air1 and Air2. In that work
many different truncation mutants and protocols were developed to successfully purify
both of the Air-proteins. Purified Air1 and Air2 have been used to characterize important
binding interactions between Air-proteins and the helicase Mtr4 (Chapter 5), as well as
binding interactions between Air-proteins and proteins that are not part of the TRAMP
complex, such as the methyltransferase Hmt1 (Chapter 6). In addition, many
crystallization trials have been initiated using Air protein truncation mutants. These
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crystallization trials include co-crystallization of Air-proteins with Mtr4 and with Hmt1.
In both of those cases, crystals have been obtained and are awaiting x-ray diffraction
analysis.
This chapter describes in detail various methods that have been developed and
used during my dissertation research on proteins from the TRAMP complex. It is
anticipated that this chapter will serve as a useful guide for future researchers studying
proteins within the TRAMP complex. Particular attention is paid to methods used for
expression and purification of the Air proteins.

EXPRESSION AND PURIFICATION OF RECOMBINANT PROTEINS

Expression and purification of Trf4
Expression analysis of isolated Trf4 was initiated by inserting the full-length Trf4
gene sequence from S.cerevisiae into a pET 151-D-topo E. coli expression vector
(Invitrogen). Primer design and insertion of Trf4 was performed following the pET 151D-topo manual. All expression tests using this full length Trf4 construct resulted in no
detectable expression. To improve expression of Trf4, PCR primers were designed to
amplify a truncation mutant of Trf4 encoding residues 113-516 (Trf4113-516). These
residues encompass the region of Trf4 exhibited in the Trf4-Air2 crystal structure (Trf4
residues 159-481) which includes the Trf4 catalytic and central domains [1]. Trf4113-516
also contains residues specified as a minimal interaction region with Mtr4 by yeast two
hybrid analysis [2, 3]. The PCR primers used for amplification were ordered from a
commercial vendor (Integrated DNA Technologies), and the full-length Trf4 construct
was used as a template for the PCR reaction. The purified PCR product was then inserted
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into an empty pET 151-D-topo vector using restriction cloning. The resulting construct
was expressed in BL21(DE3) codon+RIL E.coli cells (Agilent Technologies) using
IPTG induction and auto-induction protocols [4, 5]. Cell lysis was performed by resuspending cells in lysis buffer (10% glycerol, 500mM NaCl, 2mM β-ME, 10mM
imidazole) followed by sonication, and centrifugation. SDS-PAGE analysis indicated that
the truncated form of Trf4 was highly expressed, but the protein was only observed in the
insoluble fraction.
Denaturation and refolding of Trf4113-516
A protein denaturing-refolding protocol has been used to acquire soluble Trf4113516

. Approximately 20g of cells were re-suspended in lysis buffer, lysed by sonication,

and centrifuged. The insoluble fraction (cell-pellet from centrifugation) was then resuspended in lysis buffer containing 6M urea. The 6M Urea solution was centrifuged at
20,000 rpm and the soluble fraction was dialyzed step-wise to 250mM urea. The
following day, protein was refolded on a Ni-affinity column by adding the 250mM urea
solution to nickel resin followed by washing and eluting with solutions containing no
urea. Refolded Trf4113-516 was then further purified using heparin-affinity
chromatography. SDS-PAGE analysis revealed that this purification strategy yielded
recombinant Trf4113-516 protein that was greater than 80% pure. This refolding procedure
yielded approximately 3mg of Trf4113-516 from a 2 L growth. To date, this is the only
known protocol for purification of isolated Trf4.
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Co-expression and co-purification of Trf4-Air2

Expression construct design
For expression and purification of a Trf4-Air2 heterodimer, a pET-Duet1
expression plasmid containing the full length genes of Trf4 and Air2 was obtained from a
collaborator (Dr. Echard Jankowsky at Case Western Reserve University). This construct
contains a full-length Air2 gene with an N‐terminal 6x‐histidine tag in cloning site 1, and
the full-length Trf4 gene in cloning site 2. Using that construct as a template, a second
pETduet1 Trf4-Air2 expression construct was made. This construct is analogous to the
former except the Air2 gene has been truncated to express only amino acids 1-223. The
truncated Air2 gene was created by site directed mutagenesis following a modified
version of the QuickChangeTM Site-Directed Mutagenesis protocol (Agilent
Technologies). The only modification to the QuickChangeTM protocol was that the
recommended polymerase and buffer was substituted with PfuUltraTM polymerase and
PfuUltra Buffer (Stratagene). The Air2 mutagenesis replaced the codon encoding Air2
Ser224 with STOP224. The mutagenesis site was identified using sequence analysis and
secondary structural prediction to identify a suitable site approximately downstream of
the Air2 zinc knuckle 5 motif. The Air2 protein encoded by this construct contains the
N-terminus and all five Zinc knuckles.

Expression and purification
Co-expression of Trf4 with Air2 alleviates some of the intractable problems (such
as no expression, low solubility, and protein aggregation) that I have encountered upon
expression and purification of isolated proteins. For example, no expression is detectable
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in other constructs that contain isolated full-length versions of Air1, Air2, or Trf4. In
addition, all other constructs that contain isolated truncation mutants express proteins that
generally have low solubility and aggregate during gel filtration. In contrast, each of the
Trf4-Air2 pETduet1 constructs mentioned above express Trf4-Air2 heterodimers that are
nearly completely soluble and do not form aggregates during gel filtration.
An identical procedure has been used to express and purify each of the Trf4-Air2
heterodimers. Protein expression was induced in BL21(DE3) codon+RIL E.coli cells
(Agilent Technologies) using an auto induction protocol [5]. Cells were grown in 2.5 L
baffled Erlenmeyer flasks with a culture volume of 500 mL autoinduction media.
Appropriate antibiotics were added to the growth media for selectable resistance
(ampicillin and chloramphenicol). Because the zinc knuckles motifs of Air2 require zinc
ions to fold properly, ZnSO4 (250uM) was also added to growth media prior to
inoculation with E.coli cells. Cell cultures were incubated at 37◦ C with shaking at 300
rpm for five hours. After the initial incubation, cultures were moved to a room
temperature shaker (220 rpm) for an additional 24 hours. Cells were harvested by
centrifugation and stored at -80◦ C.

Table 4-1. Buffer solutions for Air protein preparations
Buffer component Lysis Buffer Buffer A Buffer B

Sizing
Buffer

Glycerol

10.00%

10.00%

10.00%

10.00%

HEPES pH 7.5

50 mM

50 mM

50 mM

50 mM

-ME

2 mM

2 mM

2 mM

2 mM

NaCl

500 mM

150 mM

1M

100 mM

Volume used

1 L mL

1L

500 mL

1L
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Cell lysis was performed by first re-suspending cell pellets in Lysis Buffer (Table
4-1) containing 10mM imidazole and protease inhibitors (1 µg/mL aprotinin, 1.4 µg/mL
pepstatin, and 1 µg/mL leupeptin) and lysozyme (0.2mg/mL). Approximately 3 mL Lysis
Buffer was added for every 1 mg of cells. Cells were lysed by sonication followed by
centrifugation at 20,000 rpm for 30 minutes at 4◦ C. The clarified lysate was then added
to 5 mL of Qiagen or GE brand nickel-affinity resin for 1 hour at 4◦ C. After incubation
the Ni resin was washed with 500 mL lysis buffer, followed by 200 mL Buffer B, and
then 100 mL Buffer A (Table 4-1) protein was eluted with 50 mL Buffer A containing
500 mM imidazole. Ni-column elutions were loaded directly onto a 5 mL heparin column
pre-equilibrated with Buffer A. The majority of contaminating proteins remaining after
the Ni-column step flowed through the heparin column. A 100 mL gradient from 0 to
100% Buffer B was performed using AKTA prime chromatography system. Protein
eluted from the heparin column at approximately 40% Buffer B (500mM NaCl). SDSPAGE analysis showed that the Trf4-Air2 complex was purified to greater than 80%
purity. However, two major contaminating bands (the majority of contaminants) were
observed that run approximately 5 and 10 kDa below the Air2 band. These bands were
later identified as Air2 degradation products (verified by western blot analysis). Notably,
these two degradation bands are observed in every preparation of Air1 and Air2.
The majority of Air2 degradation can be removed using a Phenyl HP hydrophobic
interaction column. Therefore, heparin elutions were dialyzed against HIC Buffer A
(Buffer A in which the salt component is 1 M AmSO4) and loaded onto a phenyl column.
The majority of all Air2 degradation products flow through the phenyl column. A 100
mL gradient of 0-100% HIC Buffer B (Buffer B in which the salt component is 100mM
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AmSO4) was then performed. After Phenyl purification the elutions were added to a
Superdex 200 26/60 gel-filtration column pre-equilibrated with Buffer A without ZnSO4.
Each of the Trf4-Air2 heterodimers elute from the gel filtration column as a single peak
according to its molecular weight. The final purified proteins are more than 97% pure and
can be concentrated (in a spin concentrator) to at least 15mg/mL. Polyadenylation
activity of purified recombinant proteins produced by this protocol has been verified by
our collaborators in the Jankowsky lab. Furthermore, I have performed this preparation
many times and tested over 2000 crystallization conditions. No crystals were obtained
from these trials. The crystal structure of Air2-Trf4 reported by Hamill et al. [1] suggests
that further truncations of Trf4 and Air2 may be required to obtain crystals.
Although Trf4-Air2 heterodimers can be successfully purified, two major
problems exist with the aforementioned protocol. The first major concern is that although
these co-expression constructs enable protein expression, the amount of expression is still
not optimal. Second, the purification procedure requires several steps over multiple days.
Together, these issues prohibit large scale production of purified proteins. The most
efficient protein preps that I conducted with these constructs and protocol yielded
approximately 1 mg of purified Trf4-Air2 from 1L culture.

Expression and purification of codon optimized Air1 and Air2

Construct design
To improve expression and purification yield of isolated Air1 and Air2 proteins,
codon optimized genes (optimized for E,coli expression) of Air1 and Air2 were
purchased from a commercial vendor (Genscript). Both of the codon optimized genes that
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were purchased contain coding sequences for the first amino acid through zinc knuckle
five (N-ZnK5). Specifically, the codon optimized gene sequences were each designed to
terminate according to the last residue of Air2 that is observed in the Air2 (ZnK4-5)-Trf4
crystal structure. In that crystal structure the last Air2 residue is aa198, which resides 31
residues down-stream of ZnK5. In the Air1 sequence, the homologous amino acid is
aa209. Accordingly, the codon optimized genes contain the sequences coding for amino
acids 1-209 of Air1 (Air1 N-ZnK5) and amino acids 1-198 of Air2 (Air2 N-ZnK5). In
addition to coding sequences, the codon optimized genes were designed to also contain
sequences at the N-terminus (preceding the coding sequence) for a TEV cleavable 6xhistidine tag and a FLAG-tag. The N-terminus of each codon optimized gene is shown in
(Figure 4-1B). The 6x-histidine tag was added to aid purification and the FLAG-tag was
added to facilitate pull-down studies using anti-FLAG resin. Each codon optimized gene
arrived from the vendor in a shuttle vector. Therefore, appropriate restriction enzyme
sites were designed to flank the N- and C-termini in order to cut and paste the sequences
directly into the expression vector pET-Duet1 (cloning site1). In addition, a BamHI site
was also designed into the sequence downstream of the FLAG-tag so that genes without
any tags could also be inserted directly into pET-Duet1 (cloning site1). As a caution to
future researchers, it should be noted that although the FLAG-tagged Air2 sequence can
be inserted directly into pET-Duet1, the BamHI sight is out of frame. This was due to a
mistake in the original sequence design. However, an in-frame Air2 (N-ZnK5) gene
sequence was PCR amplified using the codon optimized gene as a template and cloned
into empty pET-Duet1. To date, Both FLAG-tagged and non-FLAG tagged versions of
codon optimized Air1 and Air2 have been cloned into cloning site 1 of pET-Duet1.
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Figure 4-1. Air1 and Air2 codon optimized expression constructs. (A) Overview of Air1
and Air2 codon optimized gene sequence. Each construct shown has been made with and
without a FLAG-tag. (B) The N-terminus of codon optimized gene sequences.

To characterize regions of Air1 that are important for function (such as proteinprotein interactions), a variety of truncation mutants have been produced by PCR using
the codon optimized Air1 gene as a template, followed by restriction cloning into pET
duet1 (Figure 4-1A). Design of these truncation mutants focused on different ZnKs of
Air1 and the N-terminus. Each of the codon optimized Air1 genes shown in Figure 4-1
can be purified to > 90% purity.

General cautions about Air-protein preparation
Before I describe expression and purification of Air1 proteins, some words of
general caution should be given about working with the Air1 or Air2. First, although
protein expression is greatly improved by codon optimized genes, about 50-70% of
expressed protein is insoluble. This solubility issue has been observed upon expression of
all Air1 and Air2 constructs tested. Because of this problem, large growths of 4-6 liters
are typically grown for each preparation. Second, degradation products are commonly
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observed that run 5-10 kDa below Air-proteins in SDS-PAGE analysis. I have found that
the best way to avoid these degradation products is to avoid growing cells beyond the
recommended time (indicated below) and maintain protein solutions at 4◦ C throughout
the entire preparation. For example, during lysis I incubate cells in an ice slurry and avoid
sonicating more than 15 second intervals at a time. I also perform Ni-column batch
binding and elutions in the 4◦ C room. The final caution is that Air proteins are generally
prone to aggregation and precipitation. To help avoid this problem, at least 12% glycerol
should be used in all buffers; 12% glycerol is especially required during protein
concentration procedures. Protein precipitation also seems to occur while concentrating if
imidazole is present in the buffer solution. Air-proteins will also precipitate if there is a
sudden change in buffer solutions. For example, I have observed precipitation when
buffer exchanging by directly adding a volume of exchange buffer that is more than 25%
of the total protein solution volume. Buffer exchanging by dialysis also causes protein
precipitation. To avoid protein precipitation during buffer exchanges, researchers should
use gel filtration, affinity chromatography, or directly add a volume of exchange buffer
that is no more than 20 % of the total protein solution volume. Finally, protein
preparations that are prolonged to more than 72 hours typically result in protein
aggregation and precipitate. Therefore, Air proteins should be purified in less than three
days.

Expression and purification of Air1 proteins
The following general method was used to express and purify different Air1
proteins expressed by codon optimized pET-Duet1 constructs. Expression constructs
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were transformed into in BL21 (DE3) codon+RIL E.coli cells (Agilent Technologies).
Single colonies from a fresh transformation plate or a glycerol stock was used to
inoculate an overnight starter culture consisting of 30 mL LB media (in a 75 mL baffled
flask) to which ZnSO4 was added to a final concentration of 250 µM. Appropriate
antibiotics were also added to all culture media (ampicillin and chloramphenicol). Starter
cultures were grown at 37◦ C for 12-16 hours (overnight). Approximately 5 mL of the
starter culture was then used to inoculate 500 mL of media (also containing 250 uM
ZnSO4) in 2.5 L baffled flasks. The overnight culture can be used to inoculate either LB
or super-broth media (a nutrient rich media). Equal protein is produced by either growth
media, the difference between the two is cost and time. LB growths are less expensive
and require 18 hours of growth after induction, whereas super-broth growths must be
harvested 4 hours after induction. Growth beyond these time-points results in a higher
proportion of insoluble protein and protein degradation. After the overnight culture was
added, the larger cell cultures were incubated at 37◦ C with shaking at 300 rpm until
culture density reached an OD600 of 0.6-0.8 (1.5-2.5 hours). Protein expression was then
induced by adding 0.3 mM IPTG. Cultures were then moved to a room temperature
shaker (180-200 rpm) for 4-16 hours depending on the growth media (as indicated
above). Cells were harvested by centrifugation and stored at -80◦ C.
During protein purification, initial buffers including lysis buffer and buffers used
during Ni-column procedures all contained 200 µM ZnSO4. This was done to help ensure
that Air2 zinc knuckles did not exchange zinc ions for nickel ions during the Ni-column
purification step. To begin protein purification, frozen cells were re-suspended in lysis
buffer (Table 1-1) containing 10 mM imidazole and protease inhibitors (1 µg/mL
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aprotinin, 1.4 µg/mL pepstatin, and 1 µg/mL leupeptin) and lysozyme (0.2mg/mL).
Approximately 3 mL lysis buffer was added for every 1 mg of cells. Cells were lysed by
sonication followed by centrifugation at 20,000 rpm for 30 minutes at 4◦ C. The clarified
lysate was then added to 5 mL of GOLDBIO or GE brand nickel-affinity resin for 1 hour
at 4◦ C. After incubation the Ni-resin was washed with 700 mL lysis buffer, followed by
200 mL buffer B, and then 100 mL buffer A (Table 1-2). These thorough washing steps
are necessary to obtain the best purity results. Throughout all of my preparations of
different Air proteins, The Ni-column step was the most important step for purification,
and extensive washing during this step made a big difference in the final quantity of
purified protein obtained. Protein was eluted from the Ni-column in three elution steps.
Each elution contained 20 mL of buffer A containing 500 mM imidazole which was
incubated on the nickel resin for five minutes prior to elution.
The Ni-column elutions were then loaded directly onto a 5 mL heparin column
pre-equilibrated with buffer A (containing no ZnSO4). A 100 mL gradient from 0 to
100% buffer B was performed using AKTA prime or AKTA purifier chromatography
system. The Air1 proteins typically elute from a heparin column as a very broad peak that
spans about 80 mL from 30% -70% buffer B (400-800 mM NaCl). Purified protein that is
80%-90% pure is typically found in only 10-20 mL of elutions within this broad peak.
This is a point where much protein can be lost (especially if the purification during the
Ni-column step was not efficient). A typical preparation of protein from a 6 L growth
results in 10-15 mg of purified protein after heparin. If 80-90% purity is suitable then
protein can be buffer exchanged at this point and frozen. If increased purification is
needed then gel filtration can be used.
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For purification by gel filtration, Air1 protein solutions were first concentrated
using a standard spin-concentrator. Protein concentration was carried out by
centrifugation in the spin-concentrator at 2200 rpm for 15 minute intervals. Protein was
mixed sufficiently between each spin using a 1mL pipette. The protein solution was
concentrated to between 1 and 5 mL and then loaded into an injection loop of the AKTA
prime/purifier system to which a Superdex 200 26/60 column was attached. The gel
filtration column was pre-equilibrated with sizing buffer (Table 4-2) and ran overnight.
All of the Air1 proteins (and Air2 proteins) elute off of the sizing column in multiple
peaks. One peak is an Air-protein aggregate that elutes in the void volume. The other
peaks also primarily contain the Air-protein and different levels of minor contaminants.
The contaminants are generally proteins that are 70-80 kDa is size as well as Air protein
degradation products. There is always a peak containing purified protein that elutes off
the column at a volume that is consistent with an Air protein monomer. However, the size
of this peak, and the relative amount of protein that it represents has been inconsistent
between multiple preps of the same protein. The reason for this inconsistency is not
known. The best method for increasing the amount of purified Air protein monomer on
gel filtration is to use a buffer that contains at or below 100 mM NaCl. In all Air-protein
preps tested, a NaCl concentration of around 50 mM NaCl drastically reduced the
aggregate peak and increased the amount of protein obtained from the peak
corresponding to a protein monomer. The most efficient preparations Air1 (N-ZnK5) and
Air2 (N-ZnK5) from a 6 L growth after gel filtration produced only 1-2 mg of protein.
This small amount is due mainly to the fact that the majority of Air protein either elutes
as an aggregate or elutes with other contaminants. Again, the majority of contaminants
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are often Air protein degradation products, and fractions that contained these
contaminants were not pooled.

Modified purification of Air2 proteins and Air1 ZnK4-5
In addition to the above protocol, the Air2 proteins and only Air1 ZnKs 4-5 can
be purified in a much more effective way. The only difference to the Air1 purification
protocol is that a mono-Q column is used in place of a heparin column. Two Air2 protein
constructs, Air2 N-ZnK5 and N-ZnK3, and Air1 ZnKs4-5 have been purified by this
method. In each case the Air-proteins flow through the mono-Q column and all observed
contaminants stick to the column. The result is protein that is purified to greater than 98%
purity (indicated by SDS-PAGE). In addition, The Air1 ZnK4-5 that was purified using a
Q-column eluted off of a gel filtration column as a single peak without aggregation.
Furthermore 10 mg of pure protein was obtained from that prep. This is interesting
because other preps of Air1 ZnK4-5 that involved a heparin column produced a large
aggregate peak during gel filtration. The reason for this difference is not known, but the
Q-column method seems to work. Noteworthy, other Air1 proteins stick to the Q-column
without further purification. Air2 constructs have not been analyzed by gel filtration
following mono-Q purification. This should be done by future researchers.

Co-expression and purification of Air2 (N-ZnK5) and Hmt1 (K13S)
For functional studies regarding Air proteins and Hmt1, undergraduate
researchers (Emily Frampton and Kaleb Chatland) and I have begun constructing coexpression constructs of Air-proteins and Hmt1. Currently, we have been successful in
producing one of these construct which contains codon optimized Air2 (N-ZnK5) in
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cloning site 1 and Hmt1 (K13S) in cloning site 2. We have also been successful in copurifying these proteins and growing crystals of proteins purified using that protocol.

Expression and purification
Like other described protein expression methods, the Air2-Hmt1 construct was
transformed into BL21 (DE3) codon+RIL E.coli cells. A single colony from a fresh
transformation plate was used to inoculate a 30 mL LB overnight culture supplemented
with 250 µM ZnSO4 and antibiotics (ampicillin and chloramphenicol). The overnight
starter cultures were grown at 37◦ C for 16 hours (overnight). Approximately 5 mL of the
starter culture was then used to inoculate four 500 mL cultures of LB media (also
containing 250 µM ZnSO4) in 2.5 L baffled flasks. The larger cell cultures were then
incubated at 37◦ C with shaking at 300 rpm until culture density reached an OD600 of
0.3. Protein expression was then induced by adding 0.05 mM IPTG. Cultures were then
moved to a room temperature shaker that was adjusted to shake flasks at 200 rpm for 20
hours. After 20 hours, cells were harvested and stored at -80◦ C.
Cells were lysed as described above for Air1 protein preparations. The one
difference is that the lysis buffer used contained tris buffer pH 7.5, 50 mM NaCl, and no
imidazole. Low salt was used in order to ensure complex formation. Other studies have
shown that when imidazole is added, Hmt1 does not co-elute with Air2 during Ni-column
purification. Instead, when imidazole is added a higher proportion of equal molar
amounts of Air2 and Hmt1 are observed in the flow-through, suggesting that Air2-Hmt1
complexes may have a weaker affinity for Ni-resin compared to isolated Air2. Another
interesting feature that should be pointed out is that unlike isolated Air2 preparations, co-
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expression with Hmt1 results in greater than 80% soluble Air2 protein and no Air2
degradation products are observed by SDS-PAGE. After nickel column purification the
proteins are greater than 90% pure.
Nickel column elutions were pooled and concentrated to 5 mL using a spinconcentrator. The concentrator was centrifuged at 2000 rpm at 15 minute intervals and
protein was mixed sufficiently between each spin using a 1mL pipette. After
concentrating to 5 mL the protein solution was loaded into an injection loop of the AKTA
purifier system and loaded onto a Superdex 200 26/60 column. The gel filtration column
was pre-equilibrated with sizing buffer similar to that indicated in Table 4-1. The key
differences again are tris pH 7.5 and 50mM NaCl) and run overnight. The elution profile
of gel filtration showed 6 total peaks and an aggregation peak in the void volume.
According to the chromatogram, the first two peaks (indicated as peak 1 and peak 2 in lab
notebooks) were about three times larger than the other peaks. SDS-PAGE analysis
revealed that peak 2 contained the highest amount of purified Air2 and Hmt1 that
additionally appeared to be in equal molar ratio amounts. Peak 2 eluted from the gel
filtration column at 170 mL which corresponds to a protein complex of about 160-200
kilodaltons. Fractions corresponding to peak 2 were pooled and concentrated to 20
mg/mL according to the extinction coefficient for Hmt1-Air2 (N-ZnK5) which was
predicted by the ExPASy-ProtParam online bioinformatics tool [6].

Improved expression and purification of isolated Air2 (N-ZnK5)
Effective purification of isolated Air2 can be achieved by co-expressing Air2 with
Hmt1. As mentioned in the previous section, co-expression of Air2 (N-ZnK5) with Hmt1
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produces Air2 that is greater than 80% soluble and does not appear to have the
degradation products observed when Air2 is expressed alone. After co-expression with
Hmt1, stable Air2 can be isolated using buffers containing high concentrations of salt
during lysis and initial purification steps. Below, is a general description of a method
used to purify stable Air2 (N-ZnK5) after co-expression with Hmt1.

Air2 (N-ZnK5) Purification
For the following protein preparation the E.coli growth parameters and protein
expression was identical to that described above for Air2-Hmt1 co-expression. To begin
the lysis procedure, approximately 20 grams of cells (corresponding to 2 liters of LB
culture) were re-suspended in 60 mL Lysis Buffer (Table 4-2) containing protease
inhibitors (1 µg/mL aprotinin, 1.4 µg/mL pepstatin, and 1 µg/mL leupeptin) and
lysozyme (0.2mg/mL). The solution was incubated on ice 20 minutes, sonicated, and then
centrifuged at 18,000 rpm for 40 minutes. The soluble lysate was added to 7 mL GE
brand Nickel-resin (pre-equilibrated with Lysis Buffer) and incubated at 4° C on a
rotating table for 45 minutes. After incubation, the Ni-resin was added to a 50 mL handcolumn and washed with 700 mL Lysis Buffer (Table 4-2) followed by 100 mL Wash
Buffer 1 (Table 4-2). Notably, Wash Buffer 1 contains 1M AmSO4, and washes with that
buffer can be used to help remove any excess Hmt1. The Ni-resin was finally washed
with 100 mL Buffer A. Bound protein was then isolated from the Ni-resin by incubating
the resin for 5 minutes with 15 mL Buffer A containing 300 mM imidazole followed by
elution. The final elution step was repeated three times. Different preps have shown (by
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Table 4-2. Buffer solutions for Air protein preparations
Buffer component

Lysis Buffer

Wash Buffer A Buffer B
Buffer 1

Buffer C

Glycerol

10.00%

10.00%

12.00%

12.00%

12.00%

Tris pH 7.5

50 mM

50 mM

50 mM

50 mM

50 mM

-ME

2 mM

2 mM

2 mM

2 mM

2 mM

NaCl

1M

----

150mM

150 mM

100 mM

AmSO4

----

1M

----

----

----

ZnSO4

0.2M

0.2M

0.2M

0.2M

----

1L

200 mL

500 mL

500 mL

500 mL

Volume used

SDS-PAGE) that after Ni-resin purification, Air2 is typically purified to greater than 90%
purity with minor protein contaminants around 70-75 kDa in size.
Further purification of Air2 (N-ZnK5) can be obtained using an anion exchange
column. The three Ni-column elutions (described above) were pooled (~45 mL total) and
loaded onto a 5 mL mono-Q column pre-equilibrated with Buffer A (Table 4-2). A 100
mL gradient from 0 to 100% Buffer B (Table 4-2) was performed using AKTA purifier
chromatography system. Importantly, Air2 (N-ZnK5) flows through the mono-Q column
while all remaining contaminants do not, resulting in a flow-through sample that contains
stable Air2 purified to greater than 98% purity. The purified solution was then buffer
exchanged to Buffer C (Table 4-2) using a HiPrep 26/10 desalting column (GE
Healthcare Life Sciences). Buffer exchanging by gel filtration is necessary because
concentrating with imidazole present results in protein precipitation. After buffer
exchanging, the protein was concentrated to approximately 8 mg/mL followed by
addition of 20% glycerol and storage at -80° C. Air2 has been successfully purified
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multiple times using the above protocol, and each time approximately 5-10 mg of protein
was obtained per liter of cell culture. Moreover, using this protocol provides more than
tenfold the amount of pure Air2 than can be obtained without co-expression.

CRYSTALLIZATION TRIALS

Co-crystallization trials of Air2 (N-ZnK5) and Hmt1 (K13S)
Co-expressed and co-purified Air2 (N-ZnK5) - Hmt1 (K13S) complex (described
previously) was used for sitting-drop vapor diffusion crystallization screening trials using
an Art Robbins Gryphon Crystallization Robot (Art Robbins Instruments) located in the
Johnson lab. Intelli-plate 96-well crystallization plates (Art Robbins Instruments) were
used for crystallization trials. Five different crystallizations screens each containing 96
individual crystallization solutions were used to set up five 96-well crystallization plates.
The crystallizations screens used include the MCSG suite (Microlytic) which consist of
four different screens (MCSG 1-4), and the INDEX screen (Hampton Research).
Crystallization plates were incubated at 4◦ C. After three weeks protein crystals were
observed in many crystallization conditions. Crystals from MCSG 4 at location G4 in the
96 well plate (well solution is 0.1 M Sodium Citrate:HCl pH 5.6, 10% (w/v) PEG 4000,
10% (v/v) 2-Propanol) was analyzed for diffraction quality using a home-source x-ray
generator (MicroMax-007HF) and detector (Rigaku R-Axis IV++). The cryo-solution
used for these crystals consisted of the MCSG4-G4 well-solution with 15% glycerol. All
three crystals that were analyzed exhibited x-ray diffraction that was consistent with
protein crystals. The best diffracting crystal diffracted x-rays to 7 Å. Remaining crystals
in the G4-well were later analyzed by SDS-PAGE and SYPRO Ruby protein gel stain
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(SIGMA-ALDRICH). The gel analysis confirmed that these crystals contain both Air2
and Hmt1. Furthermore, another crystal from that same condition was sent to the
synchrotron source SSRL for diffraction analysis. Unfortunately that particular crystal
had poor x-ray diffraction (~20Å). However, the diffraction pattern suggested that the
crystal was indeed protein. Additionally, an x-ray excitation scan was conducted on that
crystal at SSRL which detected the presence of zinc ions, suggesting that the crystal
contained Air2 zinc knuckles. Future researchers should consider this particular crystal
hit for generating Air2-Hmt1 crystals. In addition, other crystallization hits remain
untested for diffraction quality.

Co-crystallization trials of Air2 (N-29) peptide and Mtr4
Crystallization trials have also been initiated for Air2 N-29 peptide with both full
length Mtr4 and archless Mtr4. These crystallization trials were initiated by purifying
Mtr4 proteins according to established protocols. Each of the Mtr4 proteins were
concentrated to 14-46 mg/mL in crystallization buffer (50mM Hepes pH 7.5, 5%
glycerol, 100mM NaCl, 2mM β-ME). Approximately 0.1 g of lyophilized unlabeled Air2
N-29 peptide (synthesized by Dr. Joshua Price at Brigham Young University) was also
suspended in 100 µl of the same crystallization buffer. The Air2 peptide and Mtr4
solutions were then mixed with in a molar ratio of 1.2:1.0 Air2:Mtr4. This protein
solution was incubated for 30 minutes on ice and then crystallization trials were initiated
using the same equipment and screens described above for Air2-Hmt1 crystallization
trials. The only difference is that for each Air2-Mtr4 crystallization trial, the five crystal
screens were set up at both 4◦ C and room temperature. After 3 months, several different
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crystal hits have been identified only in the trials containing archless Mtr4 at room
temperature.

Analysis of RNA binding by Air1 and Air2
To date, only one report has confirmed direct interactions of Air proteins with an
RNA substrate [7]. In that report NMR and fluorescence anisotropy studies demonstrated
that Air2 Zinc knuckles 2-4 were involved in binding hypomodified tRNAiMet, and ZnK’s
1-5 can bind a 15nt poly(A) RNA in vitro. In order to detect and further characterize
RNA binding by various recombinant Air1/2 proteins, a fluorescence based assay was
developed which monitors the change in intrinsic fluorescence of Air1/2 proteins as an
RNA substrate is titrated into an Air1/2 protein solution. This RNA binding assay has
been used to qualitatively identify binding of purified Air1 (N-ZnK5) and Air2 (N-ZnK5)
to both U6 snRNA and tRNAimet in vitro. Additional purifications of these and other
Air1/2-RNA complexes should be used for x-ray crystallography studies.
As an example of the assay procedure; purified Air1 (N-ZnK5) was concentrated
to 2 M in binding buffer (50 mM Hepes pH 7.5, 12% glycerol, 2 mM ME, 50 M
NaCl) and 1.9 mL was added to a 2 mL quartz cuvette. U6 snRNA and tRNAimet were
titrated with increasing concentrations (2 -20 M) and the change in fluorescence
between 320 nm and 400 nm was monitored using a steady-state-photon counting
spectrofluorometer, PC1 with Vinci software, from ISS Instruments (Antony lab, USU).
As shown in Figure 4-2, a significant change in fluorescence is observed after the
addition of a tenfold molar excess of RNA substrate (20 M RNA). Similar results have
also been obtained for analyzing Air2 (N-ZnK5) binding to tRNAimet. This assay can be
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Figure 4-2. Air1 (N-ZnK5) binds tRNAiMet in vitro. RNA binding results in a change
in Air1 intrinsic fluorescence. The change in fluorescence upon addition of 20 M
tRNAiMet was monitored in triplicate.

used as a qualitative assessment of Air-RNA interactions to guide potential crystallization
trials or identify RNA substrates and RNA binding regions of Air proteins. Currently, Air
protein concentrations below 2 M have not been tested and future researchers are
encouraged to investigate whether a significant change in intrinsic fluorescence (upon
RNA binding) can be observed when using nano molar concentrations of Air1/2. If
changes in fluorescence can be detected while using low enough concentrations of Air
proteins, then it is likely that a quantitative binding curve could be established to further
characterize Air-RNA binding interactions.
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CHAPTER 5
TRAMP ASSEMBLY INVOLVES BINDING INTERACTION OF
THE N-TERMINUS OF AIR2 AND THE RECA DOMAINS OF MTR4

ABSTRACT
In Saccharomyces cerevisiae many non-coding RNAs are processed and degraded
by RNA surveillance systems primarily involving the 3’-5’ exonucleolytic activities of
the nuclear RNA exosome. TRAMP complexes are exosome cofactors that identify and
polyadenylate RNAs, a process that stimulates their degradation. Each TRAMP complex
is composed of three proteins, a RNA binding protein (Air1 or Air2), a poly(A)
polymerase (Trf4 or Trf5) , and a RNA helicase (Mtr4). Previous studies have revealed
that Air2 and Trf4 form a tight complex, but how an Air2-Trf4 heterodimer associates
with Mtr4, and how formation of TRAMP modulates Mtr4 helicase activity has been
poorly characterized. Experiments reported here identify an important interaction site
between the N-terminus of Air2 and Mtr4. Additionally we show that a homologous
region of Air1 binds Mtr4, indicating common binding interfaces in different TRAMP
complexes.

INTRODUCTION
To avoid the accumulation of aberrant and unneeded RNA transcripts the
eukaryotic cell has evolved nuclear RNA surveillance pathways which ensure rapid
turnover of many types of non-coding RNAs. In these pathways a large multimeric
protein complex called the nuclear RNA exosome serves the primary role for RNA
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degradation. In Yeast, the nuclear exosome is a ring-like structure composed of nine
inactive core subunits (exo9-core) that associate with two catalytically active 3’-5’ exoribonucleases Rrp44 (exo10-complex) and Rrp6 (exo11-complex) [1-3]. In vivo, the
specificity and exonucleolytic activity of the exosome requires additional proteins that
are collectively referred to as exosome cofactors. TRAMP (Trf4p/Air2p/Mtr4p
polyadenylation complex) is a key exosome co-factor that stimulates the degradation of a
wide variety of RNA substrates including aberrant forms of tRNAs, snoRNAs, rRNA
processing intermediates, cryptic unstable transcripts (CUTs), and pre-mRNA splicing
intermediates [4-10].
TRAMP is a three-protein complex composed of a RNA binding zinc-knuckle
protein (Air1 or Air2), a non-canonical poly(A) polymerase (Trf4 or Trf5), and a RNA
helicase (Mtr4) [10-12]. In the current model of TRAMP function, Air1/2 identifies
particular RNA substrates, Trf4/5 adds a short (~4-5 nt) poly(A) tail to the 3’ end of the
RNA, and Mtr4 unwinds any RNA secondary structure that may exist [10-16]. This
unwinding and polyadenylation by TRAMP provides an unstructured single stranded 3’
end of the RNA, which is a favorable substrate for the exosome to start degrading [14]. In
this way, TRAMP plays a critical role in ridding the cell of non functional and unwanted
RNA transcripts. TRAMP mediated RNA surveillance is essential and found throughout
eukaryotic species from yeast to humans [13, 17]. In humans, defects in RNA
surveillance and processing have been linked to many disease states [18-20], highlighting
the importance of understanding the molecular details of RNA surveillance and TRAMP
complex function.
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In the yeast Saccharomyces cerevisiae, each of the Air proteins (Air1 and Air2:
45% seq. id) and Trf proteins (Trf4 and Trf5: 48% seq. id) are parologues that likely
arose as result of a whole genome duplication event in S. cerevisiae [21], and therefore
other eukaryotes have only one ortholog of each. Subsequently, in S. cerevisiae, two
general types of TRAMP complexes have been described; each one containing Mtr4 and
different combinations of Air and Trf components. TRAMP4 contains Trf4 and Air2 or
Air1, whereas TRAMP5 contains Trf5 and only Air1 [10-12, 22]. TRAMP4 and
TRAMP5 have been shown to have distinct sub-nuclear localizations, and each complex
is involved in processing specific RNA substrates. For example, Trf5-GFP and Air1-GFP
fusions are primarily enriched within the nucleolus [23-25], where rRNA transcription
and processing occurs. Accordingly, TRAMP5 preferentially enhances degradation of
aberrant rRNA precursors. TRAMP4 is required for polyadenylation and degradation of
structured RNA such as tRNAimet [12, 23], and regulating levels of transcripts encoding
proteins involved in carbon metabolism [26]. Despite these differences in RNA
specificity, growth phenotypes indicate that there is some essential functional overlap
between the different TRAMP complexes. In S. cerevisiae, none of the Trf or Air
proteins are individually essential, as single gene deletions do not result in growth defects
[27, 28]. However, a Trf4Δ Trf5Δ double mutant is inviable [29], and an Air1Δ Air2Δ
double mutant has a severe growth defect [30]. An Mtr4Δ mutant is also inviable [27].
These growth phenotypes further suggest that together the TRAMP complexes (TRAMP4
and TRAMP5) and their individual subunits perform critical functions, but why assembly
into a complex is necessary, and how different complexes are assembled is not clear.
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Several reports have indicated some functional significance of TRAMP complex
formation. A crystal structure of Air2-Trf4 and other biochemical studies have made
clear that Air2 and Trf4 form a tight complex [23, 31], and this Air2-Trf4 heterodimer is
required for Trf4 polymerase activity in vitro [10-12]. It is still unknown how Mtr4
interacts with the other TRAMP subunits. However, functional studies have revealed that
when Mtr4 is bound as part of an in-tact TRAMP complex it serves as a critical regulator
of the polyadenylation activity of Trf4 on a variety of RNA substrates [16]. Additionally,
the Air2-Trf4 heterodimer directly stimulates the helicase unwinding activity of Mtr4
[32]. This 3-way coupling between TRAMP components is presumed to ensure that a
preferred number of ~4-5 adenosines are added to the 3’end of RNA substrates, which
enhances duplex unwinding by Mtr4 and provides a docking site for the exosome [16,
32]. Although these studies highlight important aspects of TRAMP complex assembly,
how the Air2-Trf4 dimer associates with Mtr4, and how this association might facilitate
cooperative interactions between protein subunits remains to be described. Understanding
these important characteristics of TRAMP requires more detail about how the complex is
assembled. In this work, we identify a direct binding interaction between Air2 and Mtr4.
In addition, we have narrowed down a binding interface of the two proteins to be located
within the first 29 amino acids of Air2 and the ATP binding/hydrolysis domains (RecA1
and RecA2 domains) of Mtr4.
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MATERIALS AND METHODS

Recombinant protein expression and purification
The construction, expression, and purification of full length Mtr4 and Mtr4
truncation mutants have been described previously [33]. For Air1 residues 1-41, a codon
optimized gene sequence containing an N-terminal FLAG-tag followed by a 6X His-tag
was inserted into the co-expression vector pET-Duet1 and transformed into BL21(DE3)
RIL cells. Cells were grown using superbroth media, and protein expression was induced
during log-phase of growth with 0.5mM IPTG. Cells were harvested approximately four
hours after induction. Protein was purified using Nickel NTA resin followed by gelfiltration.

Fluorescence anisotropy
Binding analysis of Mtr4 to Air2 was carried out using fluorescence anisotropy.
An Air2 peptide comprising residues 1-29 with an N-terminal fluorescein label was
obtained from Dr. Joshua Price at Brigham Young University. Binding reactions were
buffered in 50 mM HEPES (pH 7.5), 100 mM sodium chloride, 0.1 mg/mL BSA, and
12% glycerol. Concentrations of the labeled Air21-29 peptide was held constant at 80 nM
and titrated with increasing concentrations of Mtr4. Samples were incubated for three
minutes after each titration, as changes in anisotropy were not observed beyond this
incubation time. Anisotropy at each titration point was measured ten times and averaged.
Anisotropy measurements were obtained using a steady-state-photon counting
spectrofluorometer, PC1 with Vinci software, from ISS Instruments. Excitation and
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emission slits were adjusted to 0.5 nm and temperature was maintained at 25°C. The
excitation wavelength was 495 nm and emission anisotropy was measured at 521 nm.

FLAG-tag pull-down studies
FLAG-tag co-immunoprecipitation was conducted using batch method in a 2mL
vessel. Purified recombinant FLAG-tagged Air1(residues 1-41) was incubated with 100l
of ANTI-FLAG M2 affinity gel (Sigma-Aldrich) and washed with binding buffer (50
mM HEPES pH 7.5, 100mM NaCl, 5% glycerol). Purified Mtr4 was then added and
incubated for 1 hour followed by additional washes with binding buffer. Bound proteins
were eluted with binding buffer containing 100 g/mL FLAG peptide, and visualized by
SDS-PAGE.

RESULTS

A 29 amino acid peptide in the N-terminus of Air2 is sufficient for Mtr4 interaction
The binding interactions that link together the three protein subunits of TRAMP
have only been described for the binding interface between Air1/2 and Trf4/5 [23, 31,
34]. However, recent reports by Holub et al. have indicated that the N-terminus of Air2 is
required for co-immunoprecipitation of an Air2-Trf4 heterodimer with Mtr4 [34],
suggesting that the N-terminus of Air2 is important for TRAMP assembly. To test
whether the N-terminus of Air2 can directly bind Mtr4, we used fluorescence anisotropy
to analyze binding between Air2 residues 1-29 and purified recombinant Mtr4. As shown
in Figure 5-1B, a fluorescently labeled Air2 peptide directly bound to full length Mtr4
with a Kd of 6.7 µM. This binding was specific as no binding was observed for this
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Figure 5-1. A 29 amino acid peptide in the N-terminus of Air2 interacts with the RecA
domains of Mtr4. (A) Domain analysis of Mtr4 and Air2. Green triangles indicate
various truncation mutants used for anisotropy analysis. B-E: Fluorescence anisotropy
analysis of a Air2 peptide binding to (B) Mtr4 full length, (C) Mtr4 with the
unstructured N-terminus deleted, (D) Mtr4 with the arch domain deleted, and (E) Mtr4
consisting of the RecA domains and a C-terminal deletion.
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peptide to other non-TRAMP proteins (data not shown). To identify the region of Mtr4
used for binding Air2, we further probed Mtr4-Air2 peptide interactions with truncated
forms of Mtr4 (Figure 5-1A). Collectively, an N-terminal truncation (Mtr4∆74, Figure 51B), an arch deletion (Mtr4archless; Figure 5-1C), and C-terminal deletion (Mtr41-614,
Figure 5-1D), all displayed similar binding affinities. Importantly, Mtr41-614 contains a
small portion of the winged helix domain (residues 576-614) and the RecA1 and RecA2
domains (domains 1 and 2 in Mtr4) which are involved in ATPase activity and RNA
binding. From these analyses we conclude that the N-terminus of Air2 directly binds to
Mtr4. Specifically, this binding interface involves the first 29 residues of Air2 and the
region of Mtr4 encompassing both of the RecA domains.

The N-terminus of Air1 can facilitate interactions with Mtr4.
Unlike Air2, Air1 is found in both TRAMP4 (Trf4/Air2(1)/Mtr4) and TRAMP5
(Trf5/Air1/Mtr4) complexes. Unique protein interactions of Air1 and Air2 within
TRAMP could be a contributing factor to various substrate specificities or functionality
of different TRAMP complexes. It is generally assumed that Air1 and Air2 use the same
conserved residues (IWRxYxL, and zinc knuckle 5) for binding Trf4 and Trf5,
respectfully [23, 34]. Therefore, we tested if both Air1 and Air2 also use a common
binding region for interacting with Mtr4. Sequence alignment of the N-termini of Air1
and Air2 indicate that Air2 residues 1-29 are homologous to the region of Air1 that
include residues 1-41 (Figure 5-2). To test if Air1 residues 1-41 can bind Mtr4, we
conducted pull-down experiments with purified recombinant Air1 residues 1-41 and
Mtr4. Figure 5-2B reveals that FLAG-tagged Air1 residues 1-41 can effectively pull
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down Mtr4 in vitro. These results indicate that Air1 and Air2 share a common region at
their respective N-termini for binding Mtr4.

Figure 5-2. Air1 residues 1-41 bind to Mtr4 in vitro. (A) Sequence alignment of
Air1 and Air2 N-termini. Identical residues are highlighted orange. Semiconserved residues are highlighted light yellow. (B) Pulldown assay with FLAGAir1 residues 1-41 and recombinant Mtr4. Bound proteins were eluted with
FLAG peptide and analyzed by SDS-PAGE

DISCUSSION
In this work we have revealed that a small peptide in Air2 can directly bind to
Mtr4, and that a homologous region of Air1 can also form a stable interaction with Mtr4.
The previous crystal structure of Air2 bound to Trf4 shows that Air2 uses its fifth zinc
knuckle and a short sequence upstream of that zinc knuckle to bind Trf4. The Air2
peptide that we have identified as binding to Mtr4 is outside of the Air2-Trf4 binding
interface, and likely represents a region used to tether the Air2-Trf4 heterodimer to Mtr4.
Furthermore, our anisotropy measurements indicate that a region encompassing the two
RecA domains of Mtr4 is used to bind the Air2 peptide, as neither the N-terminal or Cterminal domains are required for this interaction.
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Binding of Air2 to the RecA domains of Mtr4 could explain how the helicase
activity of Mtr4 is modulated in TRAMP. In Mtr4 and other Ski2-like helicases, the
RecA1 and RecA2 domains contain conserved sequence motifs for binding and
hydrolysis of ATP, a requirement for helicase function [35]. It has been shown that
TRAMP formation enhances the unwinding activity of Mtr4 by increasing Mtr4s affinity
for ATP and increasing rate constants for helicase unwinding [16]. This alteration of
Mtr4 function by Air2-Trf4 suggests that within the TRAMP complex there is a
functional coupling between Mtr4 and Air2-Trf4. It is easy to speculate that this
coupling is provided via binding of Air2 to the RecA domains, which imparts a
conformational change in structure that stimulates binding and hydrolysis of ATP. Such
an arrangement could ensure that unwinding by Mtr4 is directed at RNA substrates that
have first been identified by Air2-Trf4.
During the preparation of this manuscript Falk et al. also identified that the Nterminus of Air2 can bind directly to Mtr4 [36]. Specifically, they showed that a dimeric
protein complex (connected by a linker) of Trf4 111-490 and Air2 1-190 interacts with
Mtr4 with high affinity (Kd = 310 nM). A 49 residue deletion of the Trf4 peptide from
that construct (Trf4 160-490) resulted in lower affinity binding with Kd = 6.9 µM. This
measurement is very close to our measurements for Kd of the isolated Air2 peptide. Our
group has also identified a 26 amino acid peptide of Trf5 (residues 98-124) directly binds
Mtr4 with a modest Kd of 10 µM [37]. The sequence of that Trf5 peptide is conserved in
Trf4 residues 111-140. Thus, the amino acids corresponding to the isolated Air2 and Trf5
peptides used by our group reside within the Air2-Trf4 fusion peptide used by Falk et al.
(Trf4 111-490 and Air2 1-190 ) for their binding studies that showed tight binding to
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Mtr4 (Kd = 310 nM). Taken together, these data suggest that a small peptide region of
Air1/2 (reported in this work) and small peptide region of Trf4/5 function together to
bind Mtr4 with high affinity.
The Falk et al. manuscript also presented a crystal structure of the Air2-Trf4
fusion peptide bound to Mtr4. The model includes Mtr4 residues 117-1073, Trf4 residues
121-127, and Air2 residues 6-52. The Air2 binding interactions primarily involve Air2
residues 26, 29, 35, and 44, which form electrostatic interactions with domain 4 of Mtr4
(Figure 5-3A). Importantly, unlike our solution binding studies; Falk et al did not report
binding interactions between Air2 residues 1-29 to any portion of the RecA domains.
Instead, the crystal structure displays a sharp bend at residue 19 which directs the Nterminus of Air2 away from the bound Mtr4 molecule where it forms multiple binding
interactions to a symmetry related Mtr4 molecule. This secondary binding interface
involves Air2 residues 7, 8, 11, and a region of the Mtr4 Arch-domain known as the Fist
(Mtr4Fist, residues 665-815).
To verify if binding observed in the crystal structure between Air2 and Mtr4Fist
represents a bona fide interaction, we performed anisotropy measurements using our
labeled Air2 peptide to recombinantly purified Mtr4Fist. Figure 5-3-B shows that we
observed no binding between the Air2 peptide and isolated Mtr4Fist. Thus, our solution
binding assays and the crystal structure do not fully agree on the binding interactions
between Air2 and Mtr4. One explanation for the discrepancy is that in the crystal structure
the binding of Air2 to a symmetry related Mtr4 molecule is an artifact of crystallization,
and this crystallization-induced binding precludes native binding of Air2 residues 1-29 to
the RecA domains. Another possibility is that the interactions observed in the crystal
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Figure 5-3. Binding interactions between the N-terminus of Air2 and Mtr4Fist are not
observed in vitro. (A) Crystal structure of Mtr4 bound to Trf4 and Air2 peptides.
Zoomed- in view highlights the binding interface between the Air2 peptide and two
symmetry related molecules of Mtr4. Air2 peptide and Air2 residues involved in binding
are colored green. Mtr4 molecules are colored grey. (B) Fluorescence anisotropy analysis
of labeled Air21-29 peptide binding to recombinant Mtr4Fist.

structure may be partially influenced by the Air2-Trf4 construct, which was fused together
in a non-native conformation to facilitate crystallization.
In conclusion, we have identified a region of Air2 that directly binds to Mtr4 and
likely bridges together the three proteins of TRAMP. As described above, a recent report
has also identified that the Air2 N-terminus binds to Mtr4. However, our work goes
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beyond that described by Falk et al, as we have identified a binding interface not
observed in the crystal structure and not characterized in any other previous study.
Furthermore, this binding interface may explain modulation of Mtr4 reaction parameters
observed upon TRAMP complex formation. In addition, we identified that the
homologous region of Air1 can also bind to Mtr4 in vitro, suggesting that Air2 and Air1
use a common strategy to link the Trf4/5 and Mtr4 components in different TRAMP
complexes.
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CHAPTER 6
SUMMARY AND FUTURE DIRECTIONS

Summary: The dehydrogenases R-and S-HPCDH
Throughout biology there are few examples of homologous enzymes that function
within the same biological pathway to catalyze similar reactions with opposite
stereospecificity. This unique characteristic of R- and S-HPCDH makes them an ideal
model system to study enzymatic mechanisms of substrate recognition, specifically
stereospecificity. When I began this work a substantial amount of functional and
mechanistic studies had already characterized many stereospecific properties of R- and SHPCDH. For example, kinetic studies revealed that stereospecificity is governed by
alternative kinetic mechanisms in each enzyme [1]. However, the structural differences
between the enzymes that enable them to have opposing stereospecificity had not been
determined. Chapter 4 describes the first x-ray crystal structure of S-HPCDH, and the
first substrate-bound crystal structure of either enzyme. Using the S-HPCDH crystal
structure and a previously determined crystal structure of R-SHPCDH, I presented a
structural comparison of R-and S-HPCDH that revealed previously unknown sequence
and structural differences employed by each enzyme to facilitate stereospecificity.
The main structural difference between R- and S-HPCDH is that each enzyme has
a unique substrate binding pocket. When compared to each other, the substrate binding
pockets share a common catalytic site, but differ in orientation as they lead away from the
catalytic site to alternative substrate binding residues at the periphery of each pocket. In
addition, the substrate-bound form of S-HPCDH provided the ability to analyze substrate
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binding in these enzymes for the first time. These observations combined with previously
reported kinetic data now provide a thorough model of stereospecificity for R- and SHPCDH. In S-HPCDH, the difference in substrate binding pocket orientation provides a
binding pocket that accommodates the S-substrate isoform but sterically hinders binding
of the R-substrate isoform. Specifically, when the R-substrate (R-HPC) is modeled into
the active site of S-HPCDH the C2 methyl group clashes directly with a catalytic serine
residue. The substrate binding pocket of R-HPCDH appears to have a more open
conformation that can accommodate both substrate isomers with equal propensity.
However, as mentioned by previous models [1], binding of the S-substrate in R-HPCDH
likely leads to opposite orientation of substrate reactive groups at the catalytic site, and
therefore effective catalysis does not occur for the S-substrate in R-HPCDH. These
structural differences correlate nicely with kinetic data that indicated stereospecificity of
S-HPCDH is provided by a large difference in the value of Km between different
substrates isoforms, whereas stereospecificity of R-HPCDH is controlled by large
differences in the value of kcat between different substrate isomers. To our knowledge, the
analysis given in Chapter 4 represents the first side-by-side structural comparison of two
SDR-enzymes that function together to act upon two alcohols in the same metabolic
pathway. Furthermore, this information was essential to clarify the mechanisms of
stereospecificity used by R-and S-HPCDH in the unique pathway of bacterial epoxide
carboxylation.
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Summary: Air proteins and RNA regulation
The conserved zinc knuckle proteins Air1 and Air2 (collectively referred to as Air
proteins) are required for RNA processing and RNA surveillance in eukaryotes. Each Air
protein functions as part of a trimeric protein complex called TRAMP (TRAMP4 and
TRAMP5) [2-5], which serves to activate 3’-end degradation of targeted RNA substrates
by the nuclear exosome. Previous studies have indicated that within TRAMP4 and
TRAMP5 the Air proteins play a central role in both RNA binding and forming proteinprotein interactions [6-13] (Figure 6-1). However, the binding interactions between Air
proteins and various binding partners (protein and RNA) have remained poorly
characterized.
The research presented in this dissertation has extended the knowledge of Air
protein binding interactions, and provided a foundation for future research aimed at
exploring Air protein function. The principal finding of this work regarding the Air
proteins is the characterization of a previously unknown binding interface between Air2
and another TRAMP component, the helicase Mtr4 (Chapter 5). The binding region of
the two proteins was narrowed down to the first 29 residues of Air2 and the RecA1 and
RecA2 domains of Mtr4. Because the RecA domains of Mtr4 are used for binding and
hydrolysis of ATP, binding of Air2 to this region could explain why both ATP binding
affinity and helicase activity of Mtr4 are enhanced upon formation of the TRAMP
complex [14, 15]. Notably, binding of accessory proteins has been shown to increase
ATP affinity and helicase activity in many other helicases [16-20]. Molecular detail of
the identified Air2-Mtr4 interaction and how such an interaction modulates Mtr4 activity
remains to be determined through future biochemical and structural studies.
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7
Figure 6-1. Characterized protein-protein and RNA binding interfaces of Air proteins. Air1 and Air2 sequences are aligned with
conserved residues colored orange and semi-conserved residues colored light yellow. The indicated interactions are those
characterized for Air2 binding to Mtr4 [6], tRNA [7], Trf4 [8], and Hmt1 (unpublished data). Colored triangles indicate specific
residues of Air2 involved in protein binding. Colored circles indicate Air2 residues that are sites of posttranslational modifications
[9-11].
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In addition to binding Mtr4, the Air proteins also bind to different types of RNA
and to other proteins such as the methyltransferase Hmt1 [13, 21] (Figure 6-1). These
additional binding interactions of Air1 and Air2 are also not well characterized, and
several outstanding questions remain about Air protein function in these
processes.detailed description of future directions including existing preliminary data
aimed at answering remaining questions regarding Air protein binding interactions is
given below.

Future directions: Air proteins and protein binding interactions

Does Air2 modulate Mtr4 activity?
Fluorescence anisotropy studies have shown that Air2 residues 1-29 (Air21-29) can
directly bind to the RecA domains of Mtr4 (Chapter 5), and it was postulated that binding
of Air2 to this region may enhance ATP affinity and/or helicase activity. More
compelling evidence is required to identify if binding of Air21-29 to Mtr4 results in
modulation Mtr4 reaction parameters. This possibility can be easily tested in the Johnson
lab using routine assays to analyze Mtr4 ATP binding [15], ATP hydrolysis [22], and
helicase unwinding [22], all in the presence of unlabeled Air21-29 peptide. The Johnson
lab currently has approximately 10 mg of unlabeled Air2 1-29 peptide (synthesized by
Dr. Joshua Price at Brigham Young University) and other materials that are needed to
conduct these experiments.
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How does the N-terminus of Air2 specifically interact with Mtr4 RecA domains?
Characterization of the molecular interactions involved in forming the binding
interface between Air21-29 and the Mtr4 RecA domains requires identifying the specific
amino acids involved in binding. As mentioned in Chapter 5, Falk et al. recently reported
a crystal structure and biochemical data that also identified that the N-terminus of Air2
could associate with Mtr4 [6]. However, in that study none of the first 29 amino acids of
Air2 were reported to bind to the RecA domains of Mtr4. Instead, the crystal structure
showed that Air2 residues 7, 8, and 11 were directly bound to the Arch domain of a
symmetry related Mtr4 molecule. Using fluorescence anisotropy, I was able to
demonstrate that this interaction between Air2 and the Mtr4 Arch was likely not a
genuine interaction but rather an artifact of crystallization (Chapter 5). The Falk et al.
manuscript did however identify that residues 26 and 29 form hydrophobic interactions
with Mtr4 Met1016 (domain4; ratchet domain). In vitro pull-down studies further
confirmed this interaction, as substitution of Mtr4 Met1016 (M1016E) disrupted Mtr4
interactions with GST-Air2. Therefore, Air2 residues 26 and 29 likely form the binding
interactions described by Falk et al, and do not bind the RecA domains.
Because TRAMP complexes are found throughout eukaryotes it’s likely that
specific residues important for mediating important protein-protein interactions are also
conserved. Therefore, primary sequence analysis of various Air2 homologues might serve
as a useful tool to identify conserved residues that are important for binding to Mtr4. The
sequence alignment of the N-termini of yeast Air homologues highlights that several
residues within the first 22 amino acids are conserved or semi-conserved (Figure 6-2).
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Figure 6-2. N. terminus sequence alignment of Air protein homologues in yeast.
Conserved sequences are highlighted orange. Semi-conserved sequences are
highlighted light yellow. Residues are numbered according to Air2 sequence.

In future research, these conserved sequences should be considered for site directed
mutagenesis followed by additional binding studies with Mtr4 RecA domains to analyze
their contributions to binding. In addition, if it is also confirmed that Air21-29 can
modulate Mtr4 function, then these conserved residues are also great candidates for site
directed mutagenesis to analyze their contribution to regulating Mtr4 activity.
Obtaining a crystal structure of Air2 Air21-29 and Mtr4 would be an ideal way to
identify specific binding residues and understand how binding interactions could impact
Mtr4 function. Efforts to obtain crystals of Air21-29 and Mtr4 have been carried out with
promising success. I have initiated sitting drop co-crystallization trials with a non-labeled
Air21-29 peptide and both full length Mtr4 and an archless version of Mtr4. To date,
several different crystal hits have been identified only in the trials containing archless
Mtr4 (details can be found in Chapter 4). These crystals have not yet been analyzed for
diffraction quality nor have they been confirmed to be protein. However, it’s likely that
these crystals are indeed protein crystals, as none of the crystal hits contain crystals in the
reservoir solution and most of the crystallization solutions do not contain compounds that
typically form salt crystals. Furthermore, Regardless of diffraction quality, these initial
crystallization hits provide a great foundation for future trials.
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Do Air1 and Air2 exhibit a common binding mode for interaction with Mtr4?
In addition to fluorescence anisotropy studies which showed Air21-29 can bind full
length and truncated forms of Mtr4 with similar affinity, I also demonstrated recombinant
Air1 residues 1-41 (Air11-41) can interact with full length Mtr4 in co-IP experiments
(Chapter 5), suggesting that this region of Air1 binds to Mtr4 in a similar fashion as
Air21-29. Notably, Air11-41 consists of sequences that are homologous to Air21-29. In order
to more clearly verify that this region of Air1 and Air2 contains a common Mtr4 binding
interface, additional binding studies are needed to determine if Air11-41 also associates
with Mtr4 RecA domains, and if the binding affinity (Kd) between Air11-41 and Mtr4 is
comparable to that observed for Air21-29 and Mtr4. To this end, I have initiated
preliminary studies using florescence anisotropy to analyze binding between an Nterminal labelled Air11-41 peptide (synthesized by the Price lab at Brigham Young
University) and recombinant full length Mtr4. All of the experimental parameters (i.e.
instrumentation, buffer, temperature, protein concentrations, etc.) were analogous to
previous anisotropy studies using Air21-29 (Chapters 4 and 5) However, unlike anisotropy
studies with Air21-29, binding interactions between Air11-41 and Mtr4 was not detected.
The reason for this observed difference between the Air11-41 and Air21-29 anisotropy
results, and the discrepancy between Air11-41 anisotropy and Air11-41 co-IP results is not
clear. One possibility could be that during anisotropy studies the Air1 peptide
experiences non-specific binding interactions with itself that do not occur in the Air2
peptide or during co-IP studies. This reasoning is based on the fact that Air11-41 contains
12 additional residues (residues 4-11, 24-27) that are not observed in Air21-29 (Figure 6-2)
It is possible that during anisotropy experiments, where the Air1 peptide has free-motion
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in solution, the extra Air1 residues form non-specific binding interactions that prevent
binding to Mtr4. In contrast, the co-IP experiments were conducted by first binding the
FLAG-tagged N-terminus of Air11-41 to anti-FLAG resin prior to addition of Mtr4. This
immobilization of the N-terminus of Air1 may have prohibited non-specific binding
interactions, allowing Mtr4 to bind and co-immunoprecipitate with Air11-41. To
circumvent such a problem, future researchers should consider using other methods for
characterizing Air1-Mtr4 binding interactions in which the N-terminus of Air1 can be
attached to a solid surface and remain stationary. One such method is SPR (Surface
Plasmon Resonance), which is currently available at USU.

Future directions: Air proteins and Hmt1 regulation
In addition to their role in TRAMP mediated RNA degradation, Air1 and Air2 have
also been reported to function as regulators of nuclear mRNA export. This regulation is
attained by directly modulating the activity of the arginine methyltransferase protein Hmt1
[21]. In budding yeast, methylation by Hmt1 is required to activate the nuclear mRNA
transport protein Npl3. In its non-methylated state, Npl3 no longer effectively delivers
mRNA to the cytoplasm. Air1 has been shown to directly inhibit Hmt1 methylation of Npl3
in vitro and in vivo; suggesting that binding of Air1 to Hmt1 inhibits methylation, and thus
inhibits mRNA export. Although it is clear that Air1 can function to inhibit Hmt1, details
of how protein-protein interactions facilitate Hmt1 inhibition are unknown. In addition,
Because Air2 can bind to Hmt1 in vitro, it has been assumed that Air2 also inhibits Hmt1
activity. However, inhibition of Hmt1 by Air2 has never been reported.
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Over the last two decades, the functional importance of protein arginine
methylation has become more recognized. This post-translational modification has been
shown to regulate many critical cellular processes including DNA repair, chromatin
maintenance, gene expression, and translation [23]. Surprisingly, there are few examples
of how methylation itself is regulated within the cell. Hmt1 is the primary arginine
methyl transferase in S. cerevisiae, and Air1 is the only protein that has been shown to
regulate its activity. Understanding the mechanistic details of how Air1 inhibits Hmt1
activity would provide valuable insight to how arginine methylation is regulated in
eukaryotes. As part of my dissertation work I have initiated research to address
outstanding questions regarding Air protein mediated inhibition of Hmt1. In the text
below, I describe preliminary data and future directions aimed at answering these
questions.

How do the Air proteins bind Hmt1?
The first 54 amino acids of Hmt1 have been identified to be required for binding
the Air proteins, but which regions of the Air proteins are involved in associating with
Hmt1 have not been described. Therefore, to further identify the Air-Hmt1 binding
interface my work has focused on identifying the protein regions of Air1 and Air2
required for Hmt1 binding. As described in previous chapters, each Air protein contains
five zinc knuckles that are flanked on each side by extended N- and C-terminal
sequences. To identify which regions are important for binding Hmt1, I have designed
several expression constructs of Air1 and Air2 truncation mutants (details in Chapter 4)
which have been used to qualitatively assess Air-Hmt1 binding using in vitro pull-down
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and gel filtration analysis. Preliminary data has indicated that the extended C-terminus of
Air1 and Air2 is not required for Hmt1 binding. Pulldown experiments using FLAG-tag
Air1 indicate that an Air1 protein containing the N-terminus through zinc knuckle 5 (Air1
N-ZnK5) can bind Hmt1. Binding is also observed with a more highly truncated Air1
protein consisting of only zinc knuckles 4-5 (Air1 ZnK 4-5) (Figure 6-3A). Interestingly,
Air1 ZnK4-5 appears to pulldown Hmt1 more effectively than the longer Air1 N-ZnK5
protein. The reason for this increased binding by ZnKs 4-5 is currently not known.
Although this data clearly indicates that ZnKs 4-5 of Air1 can effectively bind Hmt1, it
does not exclude the possibility of additional binding by other regions of Air1.

A

B

Figure 6-3. Protein binding analysis of Air proteins and Hmt1. (A)
FLAG-tagged Air1 (N-ZnK5) and Air1 (ZnK4-5) pull down Hmt1 on
anti-FLAG resin. Samples were run on SDS-PAGE and visualized by
anti-His antibody. (B) Purified Hmt1 and Air2 (N-ZnK3) co-elute on
gel filtration, forming a complex with apparent 1:1 stoichiometry.
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Binding of Hmt1 by Air2 has been analyzed by gel filtration. This analysis was
conducted using individually purified Air2 (Air2 N-ZnK3) and Hmt1 proteins. Notably,
due to protein availability, Air2 N-ZnK3 was the only isolated Air2 protein used in this
experiment. Each protein was run separately and together over a gel filtration column
(Superdex 200). Analysis of the chromatogram in Figure 6-3B shows that Air2 N-ZnK3
and Hmt1 co-elute as a higher molecular weight peak compared to the individual
proteins, indicating that Air2 N-ZnK3 and Hmt1 form a stable complex in vitro. It is still
unknown whether Air2 ZnK4-5 can also bind to Hmt1. Future binding studies need to be
conducted using additional truncation mutants of both Air1 and Air2 to assess (1) if they
share common Hmt1 binding regions and (2) identify the smallest portion of each protein
that binds Hmt1. Once minimal binding regions have been identified, other binding
analyses could be used (such as ITC, SPR, fluorescence anisotropy, or EMSAs) to
quantify the various binding interactions and assess the binding contribution of particular
regions (or residues) of the Air proteins. Such studies could additionally be used to
identify tight-binding complexes that may hold promise for crystallization trials and x-ray
diffraction.
Obtaining high resolution crystal structures of Air1/2 and Hmt1 would be the
most informative piece of data to characterize the Air-Hmt1 binding interface. I have
initiated crystallization trials with Air2 truncation mutants and Hmt1 with success. These
successful crystallization trials were performed using Air2 N-ZnK5 and an Hmt1 mutant
which contained a point mutation at the thirteenth amino acid (K13S). As described in
Chapter 4, both proteins were co-expressed using a pET-Duet1 plasmid and co-purified
using affinity chromatography and gel filtration. Crystallization screening produced
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crystals in many conditions. The most promising of these hits produced protein crystals
that diffracted to 7 Å using a home-source x-ray generator at USU (Figure 6-4). An SDSPAGE gel confirmed that these crystals contain both Air2 and Hmt1. Furthermore,
another crystal from that same condition was sent to the synchrotron source SSRL for
diffraction analysis. Unfortunately that particular crystal had poor x-ray diffraction
(~20Å). However, the diffraction pattern suggested that the crystal was indeed protein.
Additionally, an x-ray excitation scan was conducted on that crystal at SSRL which
detected the presence zinc ions, suggesting that the crystal contained zinc knuckles.
Further optimization of this crystal condition may allow for x-ray diffraction of crystals
to a resolution greater than 7Å. Future researchers are encouraged to chase this crystal hit
and other crystal hits indicated in Chapter 4.

Figure 6-4. Air2 (N-ZnK5)-Hmt1 crystals
and X-ray diffraction.
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How do the air proteins regulate Hmt1 activity?
Although it has been established that Air1 inhibits Hmt1 mediated methylation of
Npl3, the mechanism of inhibition is unclear. It has also remained unclear whether Air2
also inhibits Hmt1 activity. A collaborative effort between our group (Johnson lab) and
the Hevel lab group has begun preliminary studies to identify the mechanistic detail of
Hmt1 inhibition by the Air proteins. These preliminary studies have involved using an in
vitro methyltransferase assay (developed by the Hevel lab) to monitor Hmt1 methylation
of Npl3. Using that assay it was shown that an Air1 protein consisting of N-ZnK5 can
effectively inhibit methylation by Hmt1, but an Air1 protein consisting of N-ZnK3 could
not. This observation indicates that ZnKs 4-5 of Air1 are required for inhibition of Hmt1.
This result is consistent with the pull-down binding analysis (mentioned above) which
indicated Air1 ZnK4-5 could bind to Hmt1. Interestingly, additional methyltransferase
assays showed no inhibition of Hmt1 when Air2 N-ZnK-5 was used in the reaction setup,
indicating for the first time that Air2 does not inhibit Hmt1 methylation. This result
highlights a critical flaw in the original Air-Hmt1 manuscript which concluded that Air1
and Air2 are functionally redundant in their effect of Hmt1 activity. The molecular detail
of the difference in Hmt1 inhibition by Air1 and Air2 is still unknown and is the subject
of future work.
It’s very intriguing that both Air1 and Air2 can bind Hmt1 but only Air1 inhibits
methylation. A promising avenue for identifying the specific amino acids of Air1
involved in Hmt1 inhibition is to identify sequence differences within ZnKs 4-5 of Air1
and Air2. All current knowledge indicates that both Air1 and Air2 form a tight complex
with Trf4 and Trf5 in vivo, and there is no evidence to suggest that either Air1 or Air2
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exists independent of Trf4 or Trf5 in the cell. Therefore, Air1 sequences that should be
considered as contributors to Hmt1 inhibition are those that differ from sequences in Air2
and those that are not characterized as Trf4/Trf5 binding residues. Figure 6-5 highlights
that the majority of such residues reside in the linker region (L4) between ZnK4 and
ZnK5. In future studies those residues should be the target of site directed mutagenesis
and construction of chimeric proteins. Those mutant constructs should then be tested in
Hmt1 methylation assays to define the sequences required for inhibition of Hmt1.

Figure 6-5. Sequence alignment of Air1 and Air2 zinc knuckles 4-5. Conserved residues
are colored orange. Semi-conserved residues are colored light yellow. Blue triangles
indicate residues that interact with Trf4 according to Air2-Trf4 structure (pdb 3NYB).
Red arrows indicate Air1 residues that differ from Air2, and are potential targets for
mutagenesis and functional studies. Residues are numbered according to Air2 sequence.

Conclusion
The research presented in this dissertation has provided a promising foundation
for future research efforts regarding Air proteins and their various binding interactions.
Air-Mtr4 studies have identified an important binding interaction that can be explored
using known techniques that are familiar to researchers in the Johnson lab. I have also
narrowed down another binding interface between Air1 and Hmt1. My efforts in that
project have provided a new and continuing avenue of research for both the Johnson and
Hevel labs. In addition, I have developed purification protocols and initiated
crystallization studies for both Air2-Mtr4 and Air2-Hmt1. Crystallization hits have been
identified in each case, and future repetition and modification of those studies has great
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potential for leading to high resolution crystal structures. Future researchers are strongly
encouraged to conduct follow-up crystallization studies. Furthermore, several crystals
that were produced from Air2-Mtr4 and Air2-Hmt1 crystallization trials currently remain
undisturbed in crystallization trays, and are awaiting x-ray diffraction analysis.
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